Nano-Micro Letters

, 10:53 | Cite as

A Review on Graphene-Based Nanomaterials in Biomedical Applications and Risks in Environment and Health

  • Thabitha P. Dasari Shareena
  • Danielle McShan
  • Asok K. Dasmahapatra
  • Paul B. TchounwouEmail author
Open Access


Graphene-based nanomaterials (GBNs) have attracted increasing interests of the scientific community due to their unique physicochemical properties and their applications in biotechnology, biomedicine, bioengineering, disease diagnosis and therapy. Although a large amount of researches have been conducted on these novel nanomaterials, limited comprehensive reviews are published on their biomedical applications and potential environmental and human health effects. The present research aimed at addressing this knowledge gap by examining and discussing: (1) the history, synthesis, structural properties and recent developments of GBNs for biomedical applications; (2) GBNs uses as therapeutics, drug/gene delivery and antibacterial materials; (3) GBNs applications in tissue engineering and in research as biosensors and bioimaging materials; and (4) GBNs potential environmental effects and human health risks. It also discussed the perspectives and challenges associated with the biomedical applications of GBNs.


Graphene-based nanomaterials Biomedical Delivery Biosensors Tissue engineering Bioimaging Health and environment risks 

1 Highlights

  • Structures and properties of graphene-based nanomaterials (GBNs) including graphene, graphene oxide (GO), reduced graphene oxide (RGO) and modified graphene are introduced briefly.

  • Recent advances in GBNs for the biomedical applications in drug delivery, biosensor, bioimaging and tissue engineering are summarized and analyzed.

  • Potential risks resulted from the vast production and applications of GBNs to the environment and health are discussed to ensure sustainable development of GBNs.

2 Introduction

This review focuses on the recent advances in graphene-based nanomaterials (GBNs) in the field of biomedical applications and their potential environmental and health risks. Graphene, the mother of all carbon atoms, is a single atomic thick, nanosized, two-dimensional structure and provides high surface area with adjustable surface chemistry to form hybrids. It was synthesized from graphite. In this review, we addressed the current state of the science and identified the knowledge gap for the future research development. The broad family of GBNs listed in this review includes graphene, graphene oxide (GO), reduced graphene oxide (RGO) and chemically modified graphene (that bears functional groups covalently bound to the surface of the individual layers of graphitic carbon) [1].

2.1 History of GBNs

Although carbon-based materials such as fullerene, graphite, graphene and carbon nanotubes have been widely used due to their unique properties and nanoscale dimensions [2, 3, 4, 5, 6, 7], GBNs have attracted considerable interests in recent years (2003–2018) owing to their applications in medicine, biotechnology and various interdisciplinary sciences [8, 9, 10, 11, 12, 13, 14, 15]. To date, although significant advances have been made, further studies are needed in many areas related to the multiple biomedical applications of GBNs. A graphical analysis (Fig. 1) of a number of publications was obtained from the years 2003–2017 based on the keywords ‘graphene’ and ‘biomedical applications of graphene’ using Scopus as a search engine. A growing number of publications (Fig. 1a, b) indicate new potential applications of GBNs to anticipate more emphasis on the research with these novel materials. Among GBNs, GO is one of the most potential materials for biomedical applications [16, 17, 18]. GBNs, compared to the other carbon-based materials, have the large surface area, easily modified by different functional groups and better solubility that makes them an excellent choice for biomedical use. GBNs are not homogeneous, and they vary in number, lateral dimension, surface chemistry, defect density or quality of the individual graphene sheets and composition or purity [19].
Fig. 1

a Graphical analysis of a number of publications on ‘graphene’ and b ‘biomedical applications of graphene’ for the past 14 years.

Data retrieved from Scopus

Even though graphene came into existence in the year 1859 by a British Chemist Benjamin Collins Brodie [20], it has been studied theoretically for many years by Wallace [21]. However, graphene has attracted attention among the scientific community since it was developed as a single layer of material by Novoselov et al. [22] by using the scotch tape method. The timeline of selected events in the history of graphene is highlighted (Fig. 2) [1, 23].
Fig. 2

Timeline of selected events in the history of the preparation, isolation and characterization of graphene (Figures are adapted with permission from Ref. [1]).

Copyright © 2010 WILEY-VCH Verlag GmbH and Co. KGaA, Weinheim

2.2 Structure and Properties of GBNs

GBNs have been classified based on the number of layers in the sheet, oxygen content and their chemical composition. There are many structural differences between GO and RGO which determine their physicochemical properties. Figure 3 is a schematic representation of chemical structures of graphene, GO and RGO [24]. The analytical techniques such as Raman spectroscopy, transmission electron microscopy (TEM), solid-state Fourier transform nuclear magnetic resonance (FT-NMR) spectroscopy and atomic force microscopy (AFM) are being used to understand the structural properties of GBNs [25].
Fig. 3

Schematic representation of structures of graphene, GO and RGO [24].

Copyright © Elsevier 2016

2.2.1 Graphene

Graphene is a single carbon layer of the graphite structure. It is a two-dimensional planar and hexagonal array of carbon atoms. Each of these carbons is sp2-hybridized and has four bonds, one σ bond with each of its three neighbors and one π-bond that is oriented out of the plane. It has a hexagonal pattern, forming a honeycomb crystal lattice. It is produced by mechanical or chemical exfoliation of graphite via chemical vapor deposition. It has a large specific surface area, high intrinsic mobility and high thermal conductivity. Graphene is considered as hydrophobic because of the absence of oxygen groups.

2.2.2 Graphene Oxide

GO is a single layer of graphite oxide, often produced by exfoliation of graphite oxide. GO is produced by acid–base treatment of graphite oxide followed by sonication. Several functional groups such as oxygen, epoxide groups, and carbonyl, hydroxyl and phenol groups are present on the surface of GO. The apparent difference between graphene and GO is the presence of oxygen atoms bound to carbon. GO is the product of hydrophilic derivative of graphene. GO has both aromatic (sp2) and aliphatic (sp3) domains which facilitate the interactions at the surface [26, 27, 28]. It is synthesized by the Hummer’s method and has oxygenated groups on the surface of the molecule. There is no specific structure for GO, but morphological and structural characterization gives an idea of the GO structure [29].

2.2.3 Reduced Graphene Oxide

RGO is the product of graphene oxide or graphite oxide by the chemical or thermal reduction. RGO is considered as an intermediate structure between the ideal graphene sheet and highly-oxidized GO [29]. In addition to the above structural properties of GBNs (Fig. 3), the summary of physicochemical properties of GBNs is listed (Table 1).
Table 1

Physicochemical properties of GBNs [118].

Copyright© Elsevier 2014


Single-layer graphene

Graphene oxide (GO)

Reduced GO

Young’s modulus

1000 GPa

220 GPa


Fracture strength

130 GPa

120 MPa


Optical transmittance


N/A (expected to be lower due to functional groups and defects)

60–90% depending on the reduction agent and fabrication method

Charge carrier concentration

1.4 × 1013 cm−2

N/A (much lower due to more organic nature, functional groups and defects)


Room temperature mobility

~ 200,000 cm2 V−1 s−1

N/A (expected to be much lower than 15,000 due to interruption in mobility by defects scattering)

N/A (expected to be intermediate of two due to less defects)

Thermal conductivity

~ 5000 W mK−1

2000 W mK−1 for pure 600 W mK−1 on Si/SiO2 substrate 

0.14–0.87 W mK−1

Electrical conductivity

104 S cm−1

10− 1 S cm−1

200–35,000 S cm−1

N/A not available

2.3 Synthesis of GBNs

Several approaches have been used for the synthesis of GBNs, either a ‘top-down’ or a ‘bottom-up’ approach. Figure 4 illustrates various approaches for the synthesis of GBNs [30]. Each of these methods has its advantages and disadvantages. Reina et al. (2017) emphasized that ‘bottom-up’ method is appropriate to synthesize GBNs rather than ‘top-down’ because of the non-uniformity of the synthesized GBNs which interferes with GBN-based electronic devices for biomedical applications [29]. The size, thickness and the number of layers vary based on the starting material used in the synthesis of graphene [1, 23].
Fig. 4

Schematic presentation of graphene synthesis methods—‘top-down’ and ‘bottom-up’—used for the formation of GBN hybrids and different structures. a Graphene-encapsulated NPs. b Graphene-wrapped NPs. c NPs anchored to graphene structures. d Mixed graphene-NP structures. e Graphene-NP sandwich structures. f Graphene-NP layered hybrids [30].

Copyright © 2017 Jana et al.; licensee Beilstein-Institute

Graphene was synthesized from graphite via mechanical cleavage (Scotch tape method), liquid phase exfoliation, graphite oxide/fluoride reduction, intercalation and compound exfoliation and from non-graphite sources via epitaxial silicon carbide decomposition, chemical vapor deposition (CVD) growth and bottom-up chemical synthesis [31]. Most commonly, GO can be synthesized via Hummer’s method through oxidative exfoliation of graphite using H2SO4/KMnO4 [32]. Moreover, RGO was produced from GO with the use of reducing agents hydrazine, hydrazine hydrate, L-ascorbic acid and sodium borohydride [25]. Additionally, graphene nanocomposites were prepared along with metal and metal oxide nanoparticles via in situ synthetic procedures. These in situ synthetic approaches have concerns such as obtaining uniformity of GO via top-down strategy and control of functional groups on GO, which will affect the quality and properties of GBNs [33]. To better control the size and morphology of the modified GOs, ‘binding method’ is preferred without affecting graphene’s structure. The binding method also has its limitations in size control, binding efficiency, the stability of GBNs and the distance maintenance between fluorescent components of GO and RGO’s [33]. Moreover, functionalization of GO is a vital step to enhance the GBNs for biomedical applications. Covalent and non-covalent approaches facilitate surface functionalization of GBNs to improve solubility, selectivity and biocompatibility [34]. Muthoosamy and Manickam discussed in detail the exfoliation of GBNs and ultrasound-assisted synthesis. Compared to exfoliation, ultrasonication allows synthesis of GBNs in more homogeneous state [23]. Also, Huang et al. listed multiple graphene-NP composites and their applications in various aspects of our daily life [35]. Typically, most of the synthesis approaches involved chemical reducing agents; therefore, researchers have come up with eco-friendly methods using bacteria, phytoextracts and biomolecules during the synthesis just to avoid the hazardous effects of chemical agents [36, 37].

Surface functionalization of GBNs is an essential step to further biomedical applications. Researchers studied to improve the biocompatibility, solubility and selectivity using various polymers and macromolecules such as polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), chitosan, deoxyribonucleic acid (DNA), enzymes and proteins [38].

2.4 Recent Advances of GBNs in Emerging Bioapplications

GBNs with their countless applications are expected to revolutionize various areas such as optical, electrical, thermal and mechanical fields (Fig. 5). Mainly, GBNs have received considerable attention for their potential for applications in various areas such as electronics, desalination, metal detection and removal and nuclear waste treatment [19, 39, 40]. Moreover, GO is suitable for biomedical applications such as drug delivery, gene therapy, biomedical imaging, combined cancer therapy, antibacterial agents, as biosensors. However, the actual application of any nanomaterial in biology and medicine is decided critically by its biocompatibility. To date, none of the GO applications have been approved for clinical trials. Some issues related to toxicity and biosafety became pertinent during preliminary biological application of GO [41]. Graphene materials consist of solely carbon. However, it is a matter of serious concern to understand how carbon derivatives like GO and RGO behave in a biological system and how long it takes to excrete from the human body [9]. However, during fabrication, GBNs usually undergo several chemical treatment processes for functionalization, including doping with metals, oxidation, which introduces functional groups, and also a material reduction. This indicates that some of the graphene derivatives considered for bioapplications contain metals and/or impurities other than carbon. It is known from the information on structural properties of GBNs that graphene is a hydrophobic material, so it requires modification of functional groups to make it a biomedical material. This modification may include covalent and non-covalent functionalization. Liu et al. [42] summarized the covalent and non-covalent functionalization. Non-covalent functionalization improves dispersibility, biocompatibility, reactivity, binding capacity or sensing [28]. The formation of hydrogen bonds between polar functional groups on the GO surface and water molecules forms a stable GO colloidal suspension for potential biomedical applications of GO [43, 44]. In bioapplications, both oxidized (GO) and reduced (RGO) graphene oxides are found to be feasible for drug delivery and therapeutic applications. The principal advantage of using GO over other carbon-based materials is due to its aqueous and colloidal stability. The physicochemical characteristics of GO that make it a chemically versatile template with a high surface-to-volume ratio facilitate a variety of biomedical applications such as imaging and cancer therapy, and biosensing. Apart from GO, graphene and RGO have been found to be promising photosensitizing agents for photo-ablation because they generate heat upon irradiation, making it possible for application in combined theranostic therapies.
Fig. 5

Schematic overview of medical and non-medical applications of GBNs [118].

Copyright © Elsevier 2014

3 Biomedical Applications in Therapeutics of GBNs

Therapeutics is an area of research that deals with the drug delivery and treatment of the infected biological components [45]. During the past 20 years, the rapid development of nanotechnology has brought novel materials which can be used in the diagnosis and therapeutics. Among the carbon nanomaterials, GBNs have gained popularity for their excellent physicochemical properties. Since the discovery of graphene, GBNs are considered as carrier molecules for therapeutics. Properties such as large specific area, ππ stacking and electrostatic interactions of GBNs facilitate drug loading of partially soluble drugs with high efficiency and potency [46]. GBNs are mostly used in biomedical applications for drug delivery, gene therapy and anticancer therapy.

3.1 Drug Delivery

In the past decade, nanomaterial-based drug delivery systems have been extensively investigated for the treatment of cancer, aiming at improved therapeutic efficacy and reduced toxic side effects. Since 2008, many groups have started to explore graphene-based drug delivery systems. The surface area of graphene (2600 m2 g−1) is higher, which makes them to be explored for drug delivery [27]. Basically, a monolayer of graphene represents an extreme case where every atom exposed on the surface, which allows significantly higher drug loading capacity. The two prominent modifications reported in the literature for drug delivery using GBNs are chemical modification via electrostatic interaction and binding to the aromatic molecule via ππ stacking interaction [47, 48]. One more advantage of drug delivery through GBNs is the control of release rate for sustainable drug release [49].

Single-layered GO or RGO has an ultra-high surface area available for highly efficient drug loading [42]. Recently, GO has become quite a competitive drug delivery system with the potential to be applied for systemic targeting and local effective drug delivery [50, 51, 52]. GO has unique properties such as surface area, layer number, lateral dimension, surface chemistry and purity which are relevant for their drug delivery and biological applications. In recent years, several studies have been conducted on the delivery of anticancer drugs, genes and peptides through graphene derivatives [7, 19, 24]. Approaches such as simple physisorption via ππ stacking can be used for loading many hydrophobic drugs, such as doxorubicin and docetaxel, with antibodies for the selective killing of cancer cells. Graphene is a new promising material for drug delivery via the nanocarrier approach, due to its small size, intrinsic optical properties, large specific surface area, low cost and useful non-covalent interactions with aromatic drug molecules. The large specific surface area, ππ stacking and electrostatic or hydrophobic interactions of graphene can assist in high drug loading of less soluble drugs with high efficiency and potency. Joo and his group reported that PEGylated (covalent conjugation with polyethylene glycol) GO loaded with doxorubicin (DOX) via ππ interactions shows the promising real-time release of DOX from PEGylated GO at specific loci after an external triggering by glutathione (GSH) [27]. Another research group reported that GO loaded with doxorubicin exhibits higher drug release at pH 5.3 due to the reduced interaction between DOX and the drug carrier [53]. GO loaded with DOX shows enhanced cellular toxicity and promising tumor growth inhibition, with almost 66–91% cell death. Other chemotherapy drugs, such as paclitaxel and methotrexate loaded on GO via ππ stacking and amide bonds, exhibited an amazing cancerous effect on lung cancer and breast cancer, which resulted in inhibition of about 66–90% of tumor growth. When ibuprofen, which is used as a nonsteroidal anti-inflammatory drug (NSAID), was conjugated with chitosan-functionalized GO joined by amide linkages, the functionalized GO exhibited higher (20%) biocompatibility than GO sheets for human acute lymphoblastic leukemia cell lines (CEM) and Michigan Cancer Foundation 7 cell lines (MCF-7) [54]. GO loaded with a second-generation photosensitizer chlorine 6 (Ce6) resulted in its higher accumulation in tumor cells, leading to a higher photodynamic efficacy upon irradiation. Singh et al. listed various studies on GBNs and their composites used for drug delivery systems [19].

It was expected that in 2017, there will be 1, 688,780 new cancer cases diagnosed and 600,920 cancer deaths in the USA [55, 56]. Compared to the normal tissues, tumor tissues usually possess unique microstructural features, unique microenvironment and physicochemical properties such as abnormal temperature gradients, weak acidity, overexpressed proteins and enzymes [57, 58, 59, 60]. The altered tumor intracellular environments, such as pH inside of endosomes and lysosomes, are considered when developing the anticancer drug that releases upon reaching the targeted site. For the past two decades, the rapid development in nanotechnology for the diagnosis and treatment of cancer has greatly improved. Among the carbon nanomaterials, GBNs gained popularity in anticancer research. Several studies have contributed to the delivery of GBN-based chemotherapeutics for the treatment of cancer. All great potential of graphene oxide cancer therapies encouraged many researchers to combine multifunctionalities for cancer treatment. In this section, we have summarized the recent reports on the various anticancer drugs used as therapeutics along with GBNs. Also, we have discussed the PDT and PTT used along with GBNs in anticancer therapy. Several studies reported on the delivery of anticancer drugs along with the combination of PTT and PDT. Shim et al. [24] provided a list of few anticancer therapeutics delivered using graphene nanosheets via physical absorption or chemical conjugation. They included doxorubicin, camptothecin, paclitaxel, 1,3-bis (2-chloroethyl)-1-nitrosourea, fluorouracil, methotrexate, lucanthone, β-lapachone and ellagic acid. GBNs loaded with chemotherapeutics are listed in Table 2 [24].
Table 2

GBNs loaded with chemotherapeutics [24]. Copyright © Elsevier 2016

Type of GBNs


Efficacy test




Doxorubicin-resistant MCF-7



CNE1 cells


GO with PEG


Doxorubicin-resistant MCF-7 cells




HeLa cells


Citraconic anhydride-functionalized poly(allylamine)/polyethyleneimine-GO


U87MG, MCF-7 cells


Gold nanocluster-decorated RGO


HepG2 cells




A-5RT3 cells


Poly(N-vinyl caprolactam)-grafted GO


KB cells


Poly(vinyl alcohol)-functionalized GO


MDA-MB-231 cells


Starch–graphene nanosheets


SW-620 cells


Folic acid-modified GO

Doxorubicin, camptothecin

MCF-7 cells


Poly(lactide) PEG


A549 cells


PEGylated GO

Cisplatin analog

4 T1-bearing mice


Fe3O4/graphene nanosheets


HepG2 cells


Chitosan-functionalized GO


MCF-7 cells


Gelatin-functionalized graphene nanosheets


A549 cells


Polyacrylic acid-functionalized GO

1,3-Bis (2-chloroethyl)-1-nitrosourea

GL261 cells


Graphene with PEG


U251 cells


Fe3O4/RGO, Fe3O4/GO


MCF-7 cells


RGO (modified nanoprobe)


MCF-7 cells


Poloxamer 108-GO, Tween 80-GO, Maltodextrin-GO

Ellagic acid

MCF-7, HT-29 cells


N/A not available; the numbers in the parentheses are respective references

Shim et al. [24] listed various anticancer drug categories used in combination with GBN derivatives. These include anthracycline antibiotics, quinolone alkaloids, taxanes, platinum complexes, nitrosourea compounds, pyrimidine analogs, polyphenolic compounds, quinone compounds and other chemotherapeutics [24]. Zhang et al. established a simple strategy to synthesize a 3D nanoscaled, biocompatible, reduction-responsive nanocarrier [(GON–Cy-ALG–PEG), which is used to deliver anticancer drug DOX with high loading and triggered the release of DOX. They could achieve combined chemo- and photo-thermal therapy better than routine therapy [61]. The multifunctional nanocomposite could make the specific treatment and early diagnosis of different tumors a reality.

Chemotherapy and radiation therapy are major therapeutic approaches for the treatment of a wide variety of invasive cancers today. However, one of the major disadvantages of chemotherapy and radiotherapy is their limited specificity to cancer cells, which lead to the obliteration and other damages to normal tissues and organs. Light irradiation therapeutics, including PTT and PDT, are currently the most promising technology approved by Food and Drug Administration (FDA) to attack cancer with reduced systemic toxicity and improvement of anticancer therapy [62, 63]. Sreejith et al. described schematic illustrations of PTT and PDT approaches [15]. Chen et al. outlined the recent progress in PTT-related applications of GO [64]. The intrinsic optical absorbance of GBNs in the near-infrared (NIR) region contributes to photo-thermal therapeutic use [65, 66].

The efforts to develop suitable phototherapeutic nanomaterial-targeted cancer cells or tumor are in progress [67, 68, 69, 70]. In the past few years, phototherapies based on the unique optical and chemical properties of graphene have raised interest. Compared to noble metal nanoparticles and carbon nanotube, graphene materials, especially GO, possess excellent properties such as greater optical absorption in the NIR region and higher photo-thermal conversion, high specific area and lower cost [71, 72, 73, 74]. This makes GBNs an ideal candidate for phototherapy. Within the past few years, the strong intrinsic optical absorbance of GO-hybrid materials has been intensively studied for their promising applications in in vivo cancer phototherapy [74, 75, 76, 77, 78]. PTT employs an optical-absorbing agent to generate heat under light irradiation, so biological tissues are exposed to a raised temperature to promote the selective destruction of abnormal cells. GO has attention from the PTT field due to its strong optical absorption in the near-infrared reflectance region.

Zhang et al. developed a dual-drug-loaded, doxorubicin (DOX)-loaded PEGylated nanographene oxide (NGO–PEG (polyethylene glycol)–DOX), which can deliver heat and the drug to the tumorigenic region to facilitate the combining chemotherapy and photo-thermal treatment in one system [63]. In vivo results demonstrated that the approach was superior to chemotherapy or photo-thermal treatment alone. Yang et al. constructed an iron oxide nanoparticle (CRGO-IONP) nanocomposite probe to combine the capability of tumor bioimaging with PTT [47]. Under the guidance of magnetic resonance imaging (MRI), this group found irradiation effectively ablated solid tumors with an 808-nm NIR laser at a low power density of 0.5 W cm2 with the treatment of RGO–IONP–PEG. Hu et al. synthesized a quantum-dot-tagged CRGO (QD–CRGO) nanocomposite that combines the capability of cell/tumor bright fluorescence bioimaging with photo-thermal therapy [79]. The composite mitigated the toxicity of QDs and prevented fluorescence quenching by maintaining a precisely controlled spacer between the QDs and the RGO. With a folic acid attachment, the composite could target MCF-7 cells selectively. After irradiation at 808 nm, cells were killed by the generated heat from the QD–RGO. The increased temperature also caused a marked decrease in the QD brightness, which provided a means for in situ heat/temperature sensing and an indicator of the progress of the photo-thermal therapy. Just recently, the Chung group has developed protein-functionalized RGO nanosheets of great stimuli-responsive drug delivery, controlled release and photo-thermal enhancement capability [18].

The doxorubicin (DOX)-loaded bovine serum albumin (BSA)-functionalized RGO (DOX–BSA–RGO) nanosheets demonstrated NIR-induced chemo-photo-thermal therapy of brain tumor cells treated with DOX–BSA–RGO nanosheets without causing a cytotoxic effect before cell intake. Unlike PTT, PDT relies on irradiation of photosensitizers (PSs) with a suitable light to generate free radicals, which results in irreversible damage to cancer cells. However, PDT is still a challenging technique because many of the commonly used PSs are hydrophobic and cause solubility and biocompatibility problems [45]. In efforts to this issue, Zhou et al. immobilized hypocrellin A (HA, a perylene quinonoid hydrophobic non-porphyrin photodynamic antitumor drug) onto GO via the ππ stacking interaction, hydrophobic effect and hydrogen-bonding interactions [63]. GO–HA nanomaterial could be excited by irradiation with light of an appropriate wavelength to generate singlet oxygen. The in vitro tests with HeLa cells revealed highly efficient cellular uptake of GO–HA, and the light irradiation of impregnated cells resulted in significant cell death.

To explore dual benefits of PDT and PTT, Tian et al. loaded chlorine 6 (Ce6), a photosensitizer molecule, on PEG-functionalized GO and delivered the multifaceted, complex nanosheet to KB (HeLa derivative) cells. Results show the low power density of 808-nm laser would promote the delivery of Ce6 molecules by mild local heating because of the photo-thermal effect of GO nanosheets. This is compared with Ce6 or GO–PEG–Ce6 complex without the near-infrared laser, and PDT efficacy against cancer cells was significantly enhanced [80].

Another study by Yang et al. [47] synthesized multifunctional nanocomposite GO–PEG–FA/Gd/DOX to obtain MRI and therapeutic effect. Another report on the combined chemo-photo-thermal therapy by Xu et al. [81] showed low toxic nanocomposites NGOHA–AuNRs–DOX which exhibited 1.5- and 4-fold higher cell death than separate chemotherapy and photo-thermal therapy, with biosafety and low side effects compared to non-targeting cells. Au nanoribbon (AuNR)–PEG–GO nanocomposites tested in both in vitro and in vivo showed effective chemo-photo-thermal therapy. An ideal nanocomposite combining GO with gold nanoribbon, AuNR–PEG–GO, was synthesized and used for PTT due to AuNR and GO possessing a strong NIR absorption. The composite properties of AuNR–PEG–GO would also be helpful for introducing appropriate functional groups to target specific cancer cells. The AuNR surfaces could also be a good platform through which proteins and other molecules could be linked to target specific cancer cells after inserting the appropriate cross-linkers [82].

Wang et al. developed chitosan (CS)-modified graphene nanogel for noninvasive controlled drug release. In their study, a NIR-triggered drug delivery platform based on the CS-modified chemically reduced graphene oxide (CRGO) incorporated into a thermo-sensitive nanogel (CGN) was developed. The poly(N-isopropyl acrylamide) (PNIPAM) underwent a reversible discontinuous phase transition in water, changing from hydrophilic to hydrophobic, in response to temperature change. This proved that PNIPAM hydrogel was a thermo-sensitive material. CGN exhibited a NIR-induced thermal effect similar to that of CRGO, reversible thermo-responsive characteristics at 37–42 °C and high DOX loading capacity (48 wt%). The DOX-loaded CGN (DOX–CGN) released DOX faster at 42 °C than at 37 °C. When incubated at 37 and 42 °C, DOX–CGN expression was observed in the cytoplasm of cancer cells, and nucleus, respectively, which was revealed thorough fluorescence images. Upon irradiation with NIR light (808 nm), a rapid, repetitive DOX release from the DOX–CGN was observed. Furthermore, the cancer cells incubated with DOX–CGN and irradiated with NIR light displayed significantly greater cytotoxicity than without irradiation owing to a NIR-triggered increase in temperature leading to nuclear DOX release. These results demonstrated that CGN’s promising application for on-demand drug release by NIR light is very promising [83].

Jinet al. fabricated GO-modified polylactic acid (PLA) (GO–PLA) microcapsules containing AuNPs and used them for ultrasonic (US)/computed tomography (CT) bimodal imaging-guided PTT. After the use of the microcapsules, the US/CT imaging could offer the accurate size and location of the tumor under the real-time guidance and monitoring, and then the NIR laser-induced PTT could be carried out by the diagnostic imaging results without compromising the normal tissues. This was a promising method suitable for tumor therapy [84].

Recently, a pH-responsive nanocarrier by coating nanographene oxide (NGO) with dual types of polymers, PEG and poly(allyl amine hydrochloride) (PAH), was synthesized; the PAH was then modified with 2,3-dimethylmaleic anhydride (DA) to obtain pH-dependent charge reversibility. Moreover, a chemotherapy drug (DOX) was loaded on it; this acquired NGO–PEG–DA/DOX complex exhibited a dual pH-responsiveness, showing distinctly improved cellular uptake under the tumor microenvironmental pH and augmented DOX release under lowered pH inside cell lysosomes. Combining such a unique behavior with the followed slow efflux of DOX, NGO–PEG–DA/DOX offered remarkably enhanced killing of drug-resistant cancer cells under the tumor microenvironmental pH in contrast to free DOX. The combined chemical therapy and PTT were then achieved using NGO–PEG–DA/DOX complex, realizing a synergistic therapeutic effect. This work presented a novel design of surface chemistry on NGO for the development of smart DDSs responding to the tumor microenvironment such as pH with the potential to overcome drug resistance [85].

Multimodality therapy and theranostics are going to attract great attention worldwide owing to its controllable release, minimally invasive properties and high therapeutic efficacy. The multifunctional nanocomposite shows either high photo-thermal energy conversion coefficient or NIR-triggered drug release or pH-sensitive properties or targeting properties with the real-time imaging guidance. So, the construction of other NGO-encapsulated functional nanomaterials for synergistic therapy of malignancy deserves our further efforts. Some most recent examples of multimodality therapy and theranostics are shown by Nellore et al. [86]. Their study investigated the highly selective detection of tumor cells from infected blood samples using AGE-aptamer-conjugated theranostic magnetic nanoparticle-attached hybrid graphene oxide. Their experimental data indicate that hybrid graphene can be used as a multicolor luminescence platform for selective imaging of G361 human malignant melanoma cancer cells. The reported results have also shown that indocyanine green (ICG)-bound AGE-aptamer-attached hybrid graphene oxide is capable of combined synergistic photo-thermal and photodynamic treatment of cancer. Targeted combined treatment using 785 nm NIR light indicates that the multimodal therapeutic treatment is highly effective for malignant melanoma cancer therapy. Hu et al. constructed a photo-theranostic nanoagent using indocyanine green-loaded polydopamine-reduced graphene oxide nanocomposites (ICG–PDA–RGO) and determined if the nanostructure could have amplifying PA and PTT effects for cancer theranostics. The results demonstrate that the PDA layer coating on the surface of RGO could effectively absorb a large number of ICG molecules, quench ICG’s fluorescence, and enhance the PDA–RGO’s optical absorption at 780 nm. The obtained ICG–PDA–RGO exhibits stronger PTT effect and higher PA contrast than that of pure GO and PDA–RGO. After PA imaging-guided PTT treatments, the tumors in 4T1 breast subcutaneous and orthotopic mice models are suppressed completely and no treatment-induced toxicity is observed [87].

3.2 Gene Delivery

GBNs can interact not only with the drugs, but also with other biomolecules like nucleic acids, DNA and RNA. Thus, they can be used as carriers and in the identification of nucleic acids due to large sp2-hybridized carbon area [88]. Recently, gene therapy has become an important method for treating diseases in regenerative medicine. GO has been demonstrated to adsorb nucleobases by ππ interaction and also efficiently protect nucleotides from enzymatic cleavage. The basic requirements of a gene delivery vector include protecting DNA from degradation and ensuring high transfection efficiency. Besides, viral and non-viral vectors also have been widely investigated for gene delivery research. Paul et al. [89] found that GO complexed with vascular endothelial growth factor-165 (VEGF) proangiogenic gene is an efficient deliverer for myocardial therapy. Also, graphene oxide nanosheets have been found to be suitable as a vector which is easily up taken by cells [89]. For example, Feng et al. [90] used a polyethylenimine-GO (PEI-GO) carrier to transfect the plasmid DNA into HeLa cells and showed that PEI-GO caused enhancement of the transfection efficiency by proton-sponge effect.

Non-viral gene therapy is a promising approach to treating various diseases caused by genetic disorders [91]. These carriers can transfect cells with new genes from the liquid phase in a conventionally bulky approach or from the surface of the predeposited solid phase in a substrate-mediated manner. The gene vehicle or vector must protect the loaded DNA from degradation by cellular nucleases facilitating its uptake with high transaction efficiency. The major challenge preventing the achievement of these goals is the lack of efficient and non-mutagenic vectors or gene vehicles [89, 92]. Given the unpredictability of viral vectors, many researchers have switched to synthetic vectors composed of liposomes or more recently graphene derivatives. It has been shown that GO derivatives can improve the penetration of siRNA or plasmid DNA (pDNA) into cells protecting DNA from enzyme cleavage [93]. Moreover, the cytotoxicity of cationic polyethylenimine (PEI) is significantly reduced after complexation or conjugation with GO. Also, Li et al. (2002) managed to pattern preconcentrated PEI/pDNA on absorbent GO mediating highly localized and efficient gene delivery. The patterned substrates exhibited excellent biocompatibility and enabled effective gene transfection for various cell lines including stem cells [91]. The distinguishing property of PEI-GO compared to other vehicles is its ability to condense DNA at a low mass ratio (+ 49 mV) and effectively transport pDNA through the cytoplasm to the nucleus. Also, other carbon vectors such as GO/chitosan, GO-PEG and GO/polyamidoamine (PAMAM) can also be used to deliver pDNA and siRNA. Liu et al. showed that graphene oleate PAMAM exhibited good compatibility and greatly improved green fluorescent protein gene transfection efficiency (18.3%) in contrast to ultrasonicated graphene (1.4%) and GO PAMAM without oleic modification (7.0%) [89].

Besides its ability to protect DNA, graphene possesses the unique optical property of absorbing NIR light. Tian et al. showed that localized NIR heating of GO–PEG–Ce6 increased its uptake and efficacy against cancer cells. They attributed the enhanced uptake of GO–PEG–Ce6 to an increase in membrane fluidity upon NIR heating [80]. Moreover, Kim et al. demonstrated that NIR irradiation of functionalized reduced GO can change the membrane integrity of endosomes, thus improving the intracellular lifetime of the drug or gene and their delivery efficacy [94, 95]. Tonelli et al. [7] summarized the graphene-based nanocarriers used for gene delivery.

3.3 Antibacterial Activity

Antibiotic resistance has recently become a significant health problem in the world, as there is an increase in the hospital acquired infection from multidrug-resistant pathogens [96]. However, the overuse of traditional antibiotics has led to the problem of antibiotic resistance. From the past two decades efforts have been made to invent novel drugs to treat multidrug-resistant pathogens including nanoparticles. To overcome resistance to antibiotics, many antibacterial medicines have been developed, such as metal and metal oxide nanoparticles [97]. GBNs were proven to be antibacterial because of their unique physiochemical properties. Researchers developed various GBNs-based nanocomposites via surface modification using biomolecules, polymers and inorganic nanostructures to reduce toxicity and increase their antibacterial efficiency. In this part of the section, we have summarized antibacterial activity of GBNs and their mechanism on antibacterial activity.

The versatility of GBNs and various studies confirm that GBNs could be used as antimicrobial agents [98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110]. GBNs and their nanocomposites were used as antibacterial in many fields such as in controlling microbial pathogens [111], wound dressing [112, 113], tissue engineering [114, 115, 116], packaging [117], drug delivery [118] and the purification of water [119]. Table 3 shows a recent review that lists various GBNs and their nanocomposites used as antibacterial agents. The promising applications of GBNs as antibacterial in various fields listed are drug delivery, surface infection, dental fillers, membrane antibiotic fouling, water disinfection and food packaging [120]. There are also a vast number of studies on the antibacterial activity of GO and RGO with other metal and metal oxides. GBNs were evaluated for their antibacterial activity (Table 3). In addition, the synergistic antibacterial activity of GBNs was evaluated along with other metal and metal oxides. For example, GO sheets were hybridized with silver nanoparticles (AgNPs) via one-pot hydrothermal, electrostatics interactions, simple missing chemical deposition, sequential repetitive chemical reductions and supercritical CO2. Recently, the contradictory reports on the antibacterial activity of functionalized GBNs have been discussed by Hegab et al. [120].
Table 3

Antibacterial efficiency of graphene-based nanomaterials (data adapted from Ref. [120]).

Copyright © Elsevier 2016

GBN nanocomposites

Bacterial strains

Incubation and concentration [µg mL−1]

Inhibition (%)


Graphene (G)-based nanocomposite dispersions

Graphene oxide (GO)

Pseudomona aeruginosa

2 and 175




Escherichia coli

4 and 102




E. coli

2 and 85




E. coli

2 and 40




E. coli

2 and 40



G-quantum dots

E. coli, Staphylococcus aureus

0.25 and 200



G-gelatine/silver (Ag) nanoprisms

E. coli

24 and 10




P. aeruginosa

0.5 and 5




E. coli

4 and 102




E. coli

24 and 10




E. coli/P. aeruginosa

24 and N/A

18/26 mm



S. aureus/B. subtilis

24 and N/A




E. coli

0.3 and N/A

20 mm



E. coli/S. aureus

24 and 10




E. coli/S. aureus

4 and 45



G-AgNPs/PDDA (polydiallyldimethyl ammonium chloride)

E. coli

24 and 50



G-AgNPs/PEI (polyethyleneimine)

E. coli/S. aureus

6 and 958



G-AgNPs/PDA (polydopamine)

E. coli

24 and 25

23.7 mm


G-AgNPs/PAA (poly acrylic acid)

E. col./S. aureus

24 and N/A

9.9/11.4 mm


G-AgNPs/aminophenol AgNPs/aminophenol AgNPs/aminophenol

E. coli/S. aureus

8 and 500



G-Ag/iron oxide (Fe3O4)

E. coli

24 and N/A



G-Ag/titanium oxide (TiO2)

E. coli

2 and 102




E. coli

2 and 6.6 ×105




Salmonella typhi/E. coli.

24 and 3 ×103

13/11 mm



Salmonella typhi/E. coli.

12 and 31.25/15.62



G-(MnOx), quantum dots/TiO2

E. coli/S. aureus

18 and 31.25/15.62

10.9/10.5 mm



E. coli

N/A and 102




E. coli

0.5 and N/A



G-CuNPs/poly-l-lysine PLL

E. coli

24 and 50




Mixed culture

18 and 250



G-Ag/cyclodextrin (CD)

B. subtilis

24 and 0.05



G-cadmium sulfide (CdS)

E. coli

1 and 200



G-polyethylene glycol (PEG)/PHGC (polyhexamethylene guanidine hydrochloride]

E. coli/S. aureus

1 and N/A



G-chitosan (Cs)

P. aeruginosa

24 and 3  × 103




E. coli

4 and 102




E. coli

24 and N/A

20 mm



S. aureus

20 and N/A



G-based nanocomposite Surfaces

G-AgNPs/polyamide (PA)

E. coli

1 and 103



Ag/polyethersulfone (PES) [N/A]

E. coli, S. aureus, P. aeruginosa

24 and N/A



AgNPs/cellulose acetate (CA)

E. coli

2 and N/A



AgNPs/polysulfone (PS)

E. coli

18 and N/A




S. aureus

3 and 6  × 104



Polyvinyl alcohol (PVA)/Cs

E. coli

24 and 4  × 103

8.6 mm



E. coli

4 and N/A




E. coli

1 and N/A




E. coli

24 and N/A



Polypropylene (PP)

E. coli

12 and



PLL/hyaluronic acid (HA) [105]

E. coli

4 and 105



Polyester (PE)/resin[N/A]

P. aeruginosa

24 and N/A

15 mm


PA/PLL [80]

Mixed culture

24 and 80




E. coli

24 and N/A




E. coli

1 and 103




E. coli

1 and 99.5 × 103



Stainless steel (SS)/RGO

E. coli/S. aureus

1 and N/A




E. coli/S. aureus

24 and N/A




E. coli

0.5 and N/A




E. coli/S. aureus

24 and N/A



Benzalkonium bromide (BKB)

E. coli/Listeria

48 and 4  × 103



G-based hydrogels



E. coli/Listeria

48 and 4  × 103




E. coli/S. aureus

N/A and N/A




E. coli/S. aureus

0.5 and 2.5 × 103




E. coli/S. aureus

24 and N/A



N/A not available; the numbers in the parentheses are respective references

Increasing number of investigations on the antibacterial activity of GBNs postulated several important mechanisms of antibacterial activity [120, 121]. Recently, GBNs have been widely reported to have antibacterial activity with their sharp edges to bacterial membranes leading to the destruction of lipid biomolecules and oxidative stress [121]. Zhao et al. speculated that [68] the antibacterial activity of GBNs is bacterial species dependent rather than gram dependent [122]. The antibacterial activity of GBNs involves several mechanisms together than an individual mechanism responsible for antibacterial activity (Table 3 and Fig. 6). Therefore, it is necessary to compare different types of GBNs and their effects on the bacterial species to their physiochemical characteristics. GBNs physiochemical parameters, impurities from the synthesis process, a method of antibacterial testing and experimental conditions should be considered for the GBNs which are explored for biomedical applications.
Fig. 6

Schematic mechanism of antibacterial activity of GBNs [161].

Copyright © 2016 American Chemical Society

From the above discussion, it is evident that GBNs have the potential to be used as therapeutics. GBNs have been loaded with drugs, bacteria, genes and antibacterial agents using various methods based on physisorption, chemical conjugation, gene technology and others. The loading capacity of the GBNs may differ based on the type of GBNs used, nature of drugs, viral and non-viral vectors, and antibacterial materials. Despite the development of GBN-based materials and their applications in chemotherapy, it is essential to focus more on translational research before their use as therapeutics.

4 Biomedical Applications of GBNs in Engineering

4.1 Biosensors

Biosensing, bioimaging and therapeutics are three important areas of biomedical research. These three areas are classified based on their functionality. For example, biosensing involves qualitative/quantitative recognition of the specific type of analytes by characterizing the spectrochemical, electrochemical or magneto-chemical behavior of the systems. Mostly, biosensors are useful in the detection of biomolecules and chemical analytes [15]. Biomolecules play a crucial role in the disease development, so the detection of biomolecule aids in the diagnosis and therapy is very important. GBNs can detect these biomolecules due to their excellent electrochemical and optical properties. The capacity to adsorb a variety of aromatic molecules via ππ stacking interaction makes ideal materials for fabricating biosensors [41]. Biosensors are analytical devices consisting of a biological component (receptor) and electronic component (transducer) [123]. GBNs can be used as biosensors due to their electrochemical and optical properties. They also can adsorb aromatic biomolecules through either ππ interaction or electrostatic interaction [45]. The functional groups, and electrical and optical properties of GBNs allow them to have the specific interactions at the surface of GBNs. Graphene-based biosensors were developed to detect small molecules such as glucose, nicotinamide, dinucleotide adenine, adenine triphosphate, hydrogen peroxide, estrogen [30, 33, 124, 125, 126, 127]. Also GBNs are able to detect macromolecules such as biomarkers to diagnose the disease. The commonly employed techniques such as electrochemical and fluorescence resonance energy transfer (FRET) are being used in the construction of biosensors. The other techniques such as fluorescence spectroscopy, surface plasmon resonance (SPR) and surface-enhanced Raman scattering (SERS) have also shown promising results in the detection of biosensors. Compared to conventional methods, the biosensors are enabled to quantitatively detect small molecules to large biomolecules [68]. Among GBNs, GO exhibits characteristic G-band in Raman spectra along with its water solubility and biocompatibility. Most commonly, GO-based biosensors are capable of lowering detection limits, fast response time, high sensitivity and increased signal-to-noise ratios [128]. GBN nanocomposites work efficiently in combination with metal nanoparticles, auxiliary biomolecules (chitosan), bioenzyme (horseradish peroxidase) due to their enhanced electronic and synergistic compositions to catalyze glucose enzymatic reaction for electrochemical sensing [129, 130, 131, 132]. Recent studies have explored on enzyme-based biosensors. The selective and sensitive detection of glucose was reported in the fabrication of GBN-based electrochemical glucose sensors [125, 129, 130, 133]. Other enzyme-based electrochemical biosensors have been developed using enzymes such as horseradish peroxidase (HRP), alcohol dehydrogenase (ADH), organophosphorous hydrolase (OPH), microperoxidase-11, tyrosinase, acetylcholinesterase (AChE), catalase and urease.

4.2 Bioimaging

Bioimaging is considered as the ratification of biosensing outcomes in the detection of the specific type of biological components for diagnostic purposes [45]. Bioimaging is an important aspect of diagnostic research, as it can be used to monitor the health conditions of biological components in typically two types of environments, in vivo and in vitro. The primary requirements of materials used for bioimaging are high specificity, non-toxicity and sensitivity. While graphene can alleviate the toxicity of fabricated probes, introducing the selectivity and sensitivity is still a challenge in the material synthesis. The most widely employed GBNs in bioimaging are graphene quantum dots (GQDs). The initial studies on GQDs as imaging probes were reported in the early 2000s, wherein GQDs were prepared by hydrothermal cutting of graphene sheets [21]. As these dots showed remarkable photo-physical properties, fluorescence spectroscopy was the commonly used technique for imaging biological components. Table 4 outlines various GBNs used for bioimaging.
Table 4

GBNs in bioimaging (data adapted from Ref. [33]).

Copyright © Elsevier 2016





Studies with GBNS

1 Optical imaging

Utilizes visible light and spectral properties of photons to obtain detailed images of organs and tissues

Low cost, real-time imaging, short acquisition and multiplexing capability

Poor tissue penetrability, strong tissue scattering of photons in the visible light region (395–600 nm)

Nitrogen-doped GQDs [230]

1.1 Fluorescence imaging

Noninvasive technique based on photons emitted from fluorescent probes

Minor auto-fluorescence background, larger imaging depth, reduced photo-bleaching and photo-toxicity

Cannot provide quantitative results. Interference of fluorescence quenching or photo-bleaching of fluorescent dyes, light absorption and scattering or tissues and auto-fluorescence background

nGO-PEG-Rituxan [231]


nGO–PEG–Cy7 [232]


GO–IRDye800–VEGF [231]


GO-PEG [209]

1.2 Two-photon fluorescence imaging (TPMI)

Detailed analysis of cellular/subcellular activities in the deep location of biological samples

This extends the possibility of vibrational spectroscopy with extremely high signal-to-noise ratio, negligible photo-bleaching and multiplexing capabilities to solve chemical and biochemical problems in a nondestructive and non-perturbing manner


N-GQDs [230]


Excitation wavelength in the range of 700–1350 nm


1.3 Raman imaging

It exploits the inelastic scattering of phonons derived from molecular vibrational excitation modes


Ag/GO hybrids [210]


Folic acid-conjugated Ag/GO hybrids [233]


Au@NGOs [234]


RGO-NS [235]


Au/GO and Au/RGO [236, 237]


AgCu@graphene [238]

2. Radionuclide imaging

Accurately tracks the radiolabeled substances in vivo in a quantitative manner with excellent sensitivity

PET and SPECT imaging


nGO-PEG with 1251 [232]


Low background signal and require little signal amplification


64 Cu-labeled nGO-PEG [239]


66 Ga nGO-PEG [240]


198, 199 Au@AF-GO [241]

3. Magnetic resonance imaging (MRI)

It has been used to image the anatomy as well as function of tissues in a quantitative manner with excellent spatial resolution

Noninvasive technique without ionizing radiation

Low sensitivity, long signal acquisition time

Gd–NGO [242]


GO–IONP [47]


RGO–IONP [243]


Fluorinated GO [244]

4. Photo-acoustic imaging (PAI)

It offers optical absorption contrast with the resolution of ultrasound for deep tissue/organ imaging

Radiofrequency waves exhibit lower scattering in the biological samples


RGO [245]


ICG–GO [246]


BSA-nano-RGO [247]

5. Computed tomography (CT)

It provides complementary anatomical information


Go@Ag [248]


It measures the absorption of X-rays when they pass through targets


GO/BaGdF5/PEG [249]

6. Multimodal imaging

This technique refers to integrating the merits of individual imaging modality and collecting all information from different imaging modalities that offers higher efficiency and accuracy of diagnosis

Avoids the additional stress on the body’s blood clearance that accompanies the administration of multiple doses of agents




GO–IONP–Au [250]


GO–BaGdF5–PEG [249]

The numbers in the parentheses are respective references

4.3 Tissue Engineering

Tissue engineering is an emerging new area in life sciences that targets the development of biological substitutes to modify the function of a tissue to repair and maintain its properties. These biological substitutes also known as scaffolds are made of a biodegradable material [134]. Traditional transplantation has limitations to repair tissue damage caused by trauma, infection, tumor and deformity. Materials such as hydrogels lack mechanical strength for cells to attach and spread [135]. However, different tissues in the body possess different mechanical, electrical or physical properties. Single materials might not mimic the physical and biological properties of the native tissue; therefore, hybrid bioactive materials with a variety of components that can address different requirements are widely used to fabricate artificial tissues. Hydroxyapatite [HA; Ca10(PO4)6(OH)2] is commonly used in various forms and shapes in bone and tissue engineering. However, due to their lack of mechanical strength, its usage is discouraged from replacing various parts of the bone system [136]. Materials such as hydrogels and nano-TiO2 have been used due to the lack of mechanical strength, aggregation and migration of TiO2, limiting their application in tissue engineering [134, 137, 138]. Moreover, the artificial biomarkers such as calcium phosphate (CaP), hydrogels, calcium silicate (Cs) lack the tissue inductive activity and delay the healing of functional modifications. In addition to the above, the compatibility, toxicity and anticoagulant capacity of scaffold material are other factors that limit their use in tissue engineering [137]. We discussed in Section 1.2 of this review, graphene is the basic unit of all forms of GBNs. Graphene has high mechanical strength, high surface area, high conductivity and low density. Graphene is also susceptible to acid and alkali environments and resists corrosion from the surroundings. The unique properties of GBNs, such as high elasticity, flexibility and adaptability to flat and irregular surfaces, make them suitable for the structural reinforcement of materials essential for tissue engineering which can improve adhesion, differentiation and cell function [24, 139, 140]. Among GBNs, GO can be modified easily because of the functional groups such as hydroxyl, epoxy, carboxyl on the surface of GO. Moreover GO, RGO and other graphene-based composites can be easily chemically modified because of the functional groups on the surface to interact with various biological molecules such as DNA, proteins, peptides and enzymes. On the other hand, RGO and other GO composites are being used in tissue engineering due to their flexibility to fabricate. Biomaterials like GO can induce specific cellular functions, direct cell differentiation and modulate cell–cell interactions. The fabrication strategies of graphene with biopolymer, protein, peptide, DNA and polysaccharide were discussed [141]. In the literature, it was reported that the GBNs are also applied in cardiac, neural, bone, cartilage, skeletal muscle and skin/adipose tissue engineering. The reports indicated that GBNs may also have the osteogenic and neural potential [142, 143]. GBNs antimicrobial activity supports its role in tissue engineering by reducing the infections induced by microbes to progress human health [141].

Researchers demonstrated that GO could efficiently support differentiation of stem cells. Park et al. demonstrated that GBNs could be used in stem cell culture substrate to stimulate the cardiomyogenic differentiation process of mesenchymal cells [143]. In another report, Shin et al. developed 3D multilayer tissue constructs and showed strong spontaneous beating and frequency dependency under a low external electric field [114]. The GBN nanocomposite films aid in a suitable environment for the cell growth and the production of extracellular matrix in mesenchymal cells (mMSCs) to differentiated osteoblasts for bone regeneration. Golafshan et al. investigated the cultures of PC12 cells on the scaffolds; the results indicated that these scaffolds could efficiently enhance attachment, spreading and proliferation of PC12 cells [144]. The GBNs ability to maintain high cellular viability for longer periods of time after differentiation is essential for regenerative medicine [141]. In another report, Zhou et al. evaluated GBNs stem cell-based therapies for treating bone diseases [145]. They confirmed that cartilage cells seeded on the GBNs hybrid scaffold retain chondrogenic properties and are suitable substrates. Park et al. solved the problem of the poor survival rate of mesenchymal cells implanted in myocardial tissue by using GO and fibronectin-RGO-MSC hybrids to improve cardiac function restoration [143, 146].

5 Health and Environmental Risks of GBNs

GBNs are being used in various biomedical applications in the areas of drug delivery, tissue engineering and antibacterial materials. However, considerable variations need to be addressed before the use of GBNs for treatment in humans as therapeutics. The vast production of GBNs due to their applications might lead to the significant human and environmental exposures. To address the human and environmental risk of GBNs, it is essential to evaluate the level and degree of the toxicity for the effective use of GBNs in biomedical applications [147, 148]. The biological interactions of GBNs can be categorized into biomedical applications and environmental health and safety. Occupational and environmental exposures may also lead to potential toxicity of GBNs through non-biomedical products [149]. It is essential to understand the interactions at the cellular and molecular levels to determine the toxicity of GBNs. By overcoming the challenges to be used in therapeutic delivery, the modification of GBNs in biological systems spurs up further developments in biomedical applications. From a toxicological standpoint, the physicochemical characteristics of GBNs play an essential role in assessing the extent of toxicity. For instance, dose, shape, surface chemistry, exposure route and purity play important roles in differential toxicity of GBNs [19]. Surface area, layer number, lateral dimension, surface chemistry and purity of GBNs also play a vital role in exerting the toxicity [150].

The surface chemistry of GBNs is of utmost importance for any bio-functionalization to be carried out. The surface area of the GBNs decreases as the layer number increases. The number of layers of GBNs is an important characteristic as it determines the specific surface area and bending stiffness. Whereas lateral dimension does not affect specific surface area but defines the dimension of the material, which is significant for the biological phenomena (cell uptake, renal clearance and blood–brain barrier transport) influenced by particle size [150]. Among GBNs, GO is highly reactive because of the solubility and functionalization on the surface compared to graphene and RGO. When it comes to purity, GBNs based on their synthesis process may contain unreacted and residual chemicals resulting in inadequate washing. To report the toxicity in a comprehensive approach, the above-mentioned properties need to be characterized when carrying out biological studies [150]. The route of entry of GBNs into the body via blood circulation or biological barriers may affect different organs. GBNs may enter organs by crossing blood–air barrier, blood testis barrier, blood–brain barrier and blood–placental barrier, because of their nanosize, surface structure, functionalization, charge, impurities, aggregation, corona effects and physical destructions. Several cellular mechanisms such as oxidative stress, DNA damage, inflammatory response, apoptosis, autophagy and necrosis play a significant role in GBNs toxicity [16]. Even though GBNs have suggested various biomedical applications, toxicity and biosafety are the main issues related to their biological applications.

5.1 Toxicity In Vitro and In Vivo

The toxicity of GBNs has been evaluated in different cell lines, including lung epithelial cells, fibroblasts, neuronal cells, cancer cells and animal models (Tables 5, 6). The cell death caused by nanomaterials includes either necrosis triggered by reactive oxygen species or apoptosis via plasma membrane damage. In the past few years, many reviews had published on the toxicity of GBNs in cells and animal models. The review by Ou et al. [16] summarized various toxicity studies conducted in various organs of animals and cells. The data from this review (Tables 5, 6) [16, 38] show the development of biocompatible GBNs and their toxicity effects on the cell and animal models. Moreover, Syama et al. [151] summarized approaches to reduced toxicity of graphene by using a biocompatible GBN, using microbes and plant extracts and biocompatible polymers to produce GBNs.
Table 5

GBNs toxicity effects in various cells (data adapted from Ref. [152]).

Copyright © Elsevier 2016

GBNs [Exposure conditions]

Cell types



Pristine graphene [20 µg mL−1 for 24 h]

Peritoneal macrophages; RAW264.7

Elevated transcription and secretion of cytokines and chemokines, which is triggered by activation of the NF-κB signaling pathway


Pristine graphene [0-80 µg mL−1 for 24 and 48 h]


Induction of cytotoxicity through the depletion of the mitochondrial membrane potential and the increase in intracellular reactive oxygen species, then trigger apoptosis by activation of the mitochondrial pathway


Pristine graphene; functionalized graphene [75 g mL−1 for 24 or 48 h]


High intracellular uptake of functionalized, hydrophilic graphene compared to the hydrophobic pristine graphene


Graphene; few-layer graphene (FLG) microsheets [5 h for macrophages and 24 h for other cell types]

Primary human keratinocytes; human lung epithelial cells; Murine macrophages

GBNs enter cells through spontaneous membrane penetration at edge asperities and corner sites


Graphene [N/A]

HeLa; Panc-1

The cellular responses are strongly dependent on either cell type or hard corona composition


Graphene quantum dots (GQDs) [0–200 μg mL−1, for 24, 48 or 72 h]


Induction of inflammatory response, apoptosis and autophagy in macrophages via p38 MAPK and NF-κB signaling pathways


Pluronic dispersed graphene; GO (graphene oxide) [administered directly into the lungs of mice]

Lung cells

Increased rate of mitochondrial respiration and the generation of reactive oxygen species, activating inflammatory and apoptotic pathways


Graphene, GO [20 μg mL−1; 24 h]

MDA-MB-231; B16F10

Inhibits the migration and invasion of various cancer cells by inhibiting the activities of ETC complexes


Carboxyl graphene nanoplatelets (CXYG) [0–32 μg mL−1 for 72 h]


Cytotoxicity in HepG2 cells with plasma membrane damage and induction of oxidative stress


GO [1–200 mg L−1, 24 h]


NADPH oxidase-dependent ROS formation; deregulation of antioxidant/DNA repair/apoptosis-related genes


GO [100 mg L−1 for 48 h]


Alters the miRNA expression profile


GO [0–16 μg mL−1 for 72 h]


Caused cytotoxicity in HepG2 cells with plasma membrane damage and induction of oxidative stress


GO [N/A]

RAW-264.7; Saos-2; 3T3

Impact on cytoskeleton; alterations in cell cycle


GO and its nanoassemblies [l μg mL−1; 24–72 h]

Mouse embryonic fibroblast (MEF)

Without induction of noticeable harmful effects


GO, bGO, pGO-5, pGO-30 and GS (graphene sheets) [0–200 μg mL−1, for 3 or 24 h]

Red blood cells; human skin fibroblasts

All the GO and GS show dose-dependent hemolytic activity on RBCs


GO [50 μg mL−1 for 24 h]


Higher degree of cytotoxicity and apoptosis.


GO [0–100 μg mL−1 0–5 days]

Human fibroblast cell

Dose- and time-dependent cytotoxicity, decreasing cell adhesion, inducing cell floating and apoptosis


GO [N/A]

Red blood cells

Strong hemolytic activity


GO [20–100 μg mL−1 for 0–12 h]


Cytotoxicity of GO is largely attenuated due to the extremely high protein adsorption ability of GO


GO [0–20 μg mL−1]

Peritoneal macrophage; J774A.1; LLC; MCF-7; HepG2; human umbilical vein endothelial cells (HUVEC)

Microsized GO induced much stronger inflammation responses, while nanosized graphene sheet showed better biocompatibility


GO [5–100 μg mL−1 for 24 h]


Provoked the Toll-like receptor (TLR) signaling cascades and triggered ensuing cytokine responses


GO [20 μg mL−1 for 24 h]

J774A.1; RAW 264.7

Activation of TLR4 signaling leads to GO-mediated macrophagic necrosis


GO [1–100 μg mL−1 for 24 h]

Human monocyte-derived macrophages; peritoneal macrophages

Significant impact on cellular viability, ROS generation and cellular activation


GO, PVP-GO [25–100 μg mL−1 for 48 h]

Dendritic cells

PVP-modified GO has a low immunogenicity than unadorned GO


GO, TiO2-GO [100 and 300 μg mL−1 for 4 h]


GO enters A549 cells and locates in the cytoplasm and nucleus without causing any cell damage. The TiO2–GO composite separated into GO and TiO2 after TiO2–GO composite entered A549 cells


GO, sGO [12.5 μg mL−1 for 48 h]


Inhibit Aβ peptide monomer fibrillation and clear mature amyloid fibrils


GO flake [10 μg mL−1]

Mesenchymal stem cells (MSC)

GO flakes effectively prevent a series of adverse cell signaling cascades that result in the anoikis of MSCs in response to ROS


GO [37.5 μg mL−1 FITC-PEG-GOs for 2 h]

Saos-2; HepG2; RAW-264.7

Processes such as micropinocytosis, microtubule-dependent mechanisms, clathrin-dependent mechanisms and phagocytosis are involved


GO [20–50 μg mL−1 for 30 min–14 h]


Cells enter through clathrin-mediated endocytosis, and the increase in graphene size enhances phagocytotic uptake of the nanosheets


GO [40 or 80 μg mL−1 for 24 h]

MDA-MB-231; MDA-MB-436; SK-BR-3

PEG-GO inhibited the migratory and invasive properties of human metastatic breast cancer cell lines by inhibiting ATP synthesis, leading to a disruption of F-actin cytoskeletal assembly




No apparent toxicity as drug carrier




No apparent toxicity as drug carrier


Oxidized graphene nanoribbons (O-GNR) [10–400 μg mL−1 for 12–48 h]

HeLa; NIH-3T3; SKBR3; MCF-7

Dose-dependent and time-dependent cytotoxic effects on the four cell lines


O-GNR [50 μg mL−1 for 30 min]

MCF-7; A549; MRC5

Significant O-GNR-PEG-DSPE uptake into cells with high EGFR expression



U251; CG-4; MCF-7

No apparent toxicity as drug carrier


O-GNR [0–100 μg mL−1 for 24 h]


GONRs with concentrations ≤ 50 μg/mL showed no significant cytotoxicity; GONRs with a concentration of 100 μg/mL exhibited significant cytotoxicity and resulted in a decrease in cell growth and induction of cell apoptosis


O-GNR, GNO and GONP [0–300 μg mL−1 24–72 h]


GNOs, GONRs and GONPs at concentrations of less than 50 μg/mL for 24 or 72 h could be considered potentially safe incubation conditions for ex vivo labeling for MSCs


GO; RGO [200 μg mL−1 24 h]


Protein-coated graphene resulted in a markedly less cytotoxicity than uncoated graphene


GO, RGO [10 μg mL−1]


Significant increase in both intercellular ROS levels and mRNA levels of HO1 and TrxR. Moreover, a significant amount of DNA damage is observed in GO-treated cells, but not in RGO-treated cells


GO, RGO [0.0125–12.5 μg cm−2 for 5 days]

A549; RAW 264.7

Lower concentrations of GO/RGO did not lead to an increase in ROS production. Cellular internalization of GO was observed in phago(endo)somes without signs of any intracellular damage.


RGO/HARGO (hyaluronic acid GO) [20 μg mL−1 for 24 h]


No significant cell death observed in the absence of NIR irradiation




No apparent toxicity as drug carrier


RGO [1–200 mg L−1 for 24 h]


Hydrophobic RGO was found to mostly adsorbed at cell surface without internalization, ROS generation by physical interaction, poor gene regulation


RGO [1–100 μg mL−1 24 h]

Human blood cells; HUVEC

The biocompatible biopolymer-functionalized RGO exhibited excellent biocompatibility


RGO, GONP, RGONP [0.01–100 μg mL−1 for 24 h]


The RGONPs exhibited a strong potential in destruction of the cells with the threshold concentration of 1.0 mg/mL, while the cytotoxicity of the RGO sheets appeared at high concentration of 100 mg/mL after 1 h


GO, RGO [1–10 μg mL−1 for 24 or 48 h]


GO exhibits higher toxicity than RGO due to ROS generation. Small flake size graphene exhibits greater cytotoxicity compared to larger sheets due to intracellular accumulation of graphene


GO, RGO [0–20 μg mL−1]

Human platelets

GO can evoke strong aggregatory response in platelets comparable to that elicited by thrombin


GO, RGO, G-NH2 [2–10 μg mL−1 for 3 h]

Red blood cells

G-NH2 is not endowed with thrombotoxic property


GO, RGO [100 μg mL−1]

U87 U118

Reduction in cell viability and proliferation and induced apoptosis


RGO [50 μg mL−1]


Reduction in GBM tumor volume was observed. RGO + Arg shows antiangiogenic and proapoptotic characteristics


The numbers in the parentheses are respective references

Table 6

GBNs toxicity effects in various animal models (Data adapted from [16, 296, 297, 298])

GBNs and exposure conditions

Animal model



Nanoscale graphene oxide (NGO) [0, 1, 5, 10 mg kg−1, intratracheal instillation 0 h, 24 h, 48 h, 72 h and 1 week]

C57BL/6 mice

Acute lung injury (ALI) and chronic pulmonary fibrosis


Few-layer graphene (FLG) [0.1, or 1 mg mL−1, oral gavage or intratracheal instillation 3 or 28 days]

ICR mice

Intratracheally instilled FLG acute lung injury and pulmonary edema, FLG did not show detectable absorption through the gastrointestinal tract by oral gavage


Graphene platelets (GPs) [inhalation exposure, 1 day–6 weeks]


GP caused acute inflammation in lung at 1 day and alleviated inflammation in lung after 6 weeks


Graphene nanoplatelets (GPs) [50 μg per mouse, pharyngeal aspiration or intrapleural installation, 24 h–7 days]

Female C57BL/6 strain mice

Large GPs were inflammogenic in both the lung and the pleural space


GO [0.5 or 4 mg m−3, inhalation exposure, single 6 h]

Sprague–Dawley rats

The single inhalation exposure to GO induces minimal toxic responses in rat lungs


GO [1.0 mg kg−1, intravenously injected, 24 h]

Male ICR mice

Accumulated mainly in the liver and lungs


GO [24 mg kg−1, tail vein injected, 5 days]

Male and female ICR-strain mice

Did not affect pup numbers, sex ratio, weights, pup survival rates or pup growth, low toxicity for male reproduction


GO [1,10 mg kg−1, intravenous injection 14 days]

Kunming mice

Led to high accumulation, long-time retention, pulmonary edema and granuloma formation


NGO–PEG [5 mg kg−1, tail intravenous injection 10 min-24 h]

Male Kunming mice

NGO–PEG alleviated acute tissue injuries and decreased the early weight loss


GO, GO–PEG, RGO–PEG, nRGO–PEG [4 mg kg−1, intraperitoneal injection 1, 7 and 30 days]

Balb/c mice

Accumulated in the reticuloendothelial system (RES) including liver and spleen over a long time


GO, graphene quantum dots (GQD) [20 mg kg−1 intravenous injection or intraperitoneal injection 14 days]

Balb/c mice

GO appeared toxic and caused death GQD revealed no accumulation in organs and caused low cytotoxicity


Purified graphene oxide (pGO) [50 μg/animal, intraperitoneal injection 24 h, 7 days]

Female C57Bl/6 mice

Induced moderate inflammation and granuloma formation following


GO [series concentrations, subcutaneous injection 21 days]

C57BL/6 male mice

The microsize of GO induced much stronger inflammation responses than the nanosized GO


GO [2 or 20 mg kg−1, subcutaneous and intraperitoneal injection]

C57BL/6 J mice

Both GO and a reduction in GO result in immune cell infiltration, uptake and clearance


RGO-iron oxide nanoparticles (RGO-IONP) [400 μg, subcutaneous injection]

Female Balb/c mice

RGO–IONP can effectively inactivate multiple-drug-resistant bacteria in subcutaneous abscesses


GO, GO-PEG [100 mg kg−1, oral administration; 50 mg kg−1, intraperitoneal injection, 1, 7 and 30 days]

Female Balb/c mice

No obvious tissue uptake via oral administration, indicating the rather limited intestinal adsorption of those nanomaterials


RGO [60 mg kg−1, oral gavage, 5 days]

Male C57black/6 mice

RGO affected general locomotor activity, balance and neuromuscular coordination, but showed little change in exploratory, anxiety-like or learning and memory behaviors


GO [0.76 ± 0.16 − 9.78 ± 0.29 mg m−3,6 h/day for 5 days]

Male Sprague–Dawley rats

No significant systemic effects of toxicological importance were observed. Only minimal or unnoticeable GO toxicity in the lungs and other organs


Graphene [0.12–1.88 mg m−3, 6 h/day and 5 days a week].

Male Sprague–Dawley rats

No dose-dependent effects and no distinct lung pathology were observed. This study suggested low toxicity, and a NOAEL of no less than 1.88 mg/m3 was recorded for the body weights, bronchoalveolar lavage fluid inflammatory markers and blood biochemical parameters


Graphene [0.68 ± 0.14–3.86 ± mg m−3, 6 h/day and 5 days a week]

Male Sprague–Dawley rats

Minimal toxic effect at the concentrations and time points in this study


The two aspects that demonstrate the behavior of GBNs in biological fluids are the behavior of graphene as a colloid and the formation of the graphene surface of the protein corona. The GBNs in colloid form interact with the physiological media resulting in aggregation and flocculation of the suspension. Another critical factor affecting the behavior of GBNs is the formation of a protein corona. They explain that two components (soft and hard corona) play a significant role in adsorbing proteins. The particle stability may be enhanced if proteins are adsorbed via hydrophobic region to the basal plane of the flake with the hydrophilic region directed toward the exterior. On the other hand, adverse reactions may occur with the biodistribution and the interaction with the immune system. Hence, it is confirmed that the systemic adverse reactions are caused by GBNs or by modifications performed to GBNs [148]. Cells exposed to nanomaterial may undergo both apoptosis and necrosis. Chemical and physical properties such as reactive oxygen species (ROS) and direct damage to plasma membrane may trigger apoptosis and necrosis respectively. Figure 7 illustrates various toxicity mechanisms of toxicity at the cellular level [151]. Many reports were published on the internalization of GBNs as therapeutic agents as well as they might lead to cell intoxication [152]. The complication of intravenous drug delivery of GBNs bioaccumulation and granuloma formation can be overcome by surface modifications to accomplish selective targeting and support biodegradation [150].
Fig. 7

Mechanisms of toxicity of GBNs [151].

Copyright © 2016 Elsevier B.V

It is evident from the literature [16] that in vitro toxicity results suggest that GBNs can be mostly toxic, but the toxicity is dependent on various factors such layer number, lateral size, stiffness, hydrophobicity, surface functionalization and dose. The four routes for entry of any nanoparticle into the human body include inhalation, ingestion, dermal penetration and injection or implantation for biomedical applications [150]. The route of entry, the dose and the duration of nanoparticles into the human body have a significant effect on the extent and severity of the toxicity [16]. The other significant determinants such as dose and duration of exposure also play a vital role in the level of toxicity.

5.2 Impact on the Environment

Graphene is emerging as a dynamic nanocarbon material. Although there are a broad scope and numerous advantages of GBNs in different fields of the scientific world, they also cause toxic effects on different biological models. An increase in the production of GBNs and their expected usage for biomedical purposes raises anxiety about their effects on humans and environment. It is necessary to understand the interaction of GBNs with the living systems to advance the biomedical application of GBNs. Even though the health effects associated with the GBNs have been studied at the cellular and in animal model, the human exposure of GBNs is unknown. Humans can be affected by GBNs via various exposure routes (Fig. 8) [151] from the site of production to the environment. Thereby, both the abiotic and biotic compartments of the ecosystem will get disturbed. It is imperative to investigate the interaction of GBNs across the membranes in the ecosystem to estimate the risk potential of the GBNs released into the environment. Very few reports found the impact of GBNs on the environment. Among GBNs, GO is considered as toxic. Choudhury et al. and Wu et al. investigated the environmental fate and transport of GO [153, 154, 155, 156]. Choudhury et al. investigated the role of sunlight on the physicochemical properties, aggregation and deposition of GO in aquatic environments [155]. They reported that exposure to sunlight has a significant impact on the physiochemical properties of GO and their subsequent transport by reducing the materials stability in the environment. The research needs to be conducted to understand the complex roles of pH, natural organic material and other natural colloids on the fate of photo-transformed GO. Zhao et al. [122] discussed GO transformation to RGO may occur under the direct interaction of aquatic organisms. Hua et al. explored the aggregation and resuspension of GO in simulated natural aquatic environments. The findings indicated that the graphene oxide nanoparticles (GONPs) transport and fate has a significant impact in natural aquatic environments by divalent cations, natural organic matter (NOM) and hydraulics [157].
Fig. 8

Human exposure to graphene from the environment: Humans are exposed to nanomaterials either intentionally in the form of therapy or unintentionally via various factors especially during the manufacturing process in industries. Graphene can enter ecosystem mainly through waste disposal from industries or pharmaceuticals, posing a threat to aquatic organisms. Stable graphene that exists in soil or water can enter the human body through food chain [151].

Copyright © 2016 Elsevier B.V

As it is projected that the GBNs-based products market to reach millions of dollars by 2020, there will be a generation of GBNs-based wastes into the environment. It is essential to evaluate the potential toxic effects and fate of GBNs in the environment. Only a few researchers evaluated the impact of GBNs in environment. Ahmed et al. investigated the acute effects of GO on waste water microbial community [158]. They concluded that GO was toxic to microbial communities in concentrations between 50 and 300 mg L−1. The quality of the effluent was deteriorated by increasing the turbidity of water and the reduction in sludge dewaterability. They also confirmed the reactive oxygen species generation is responsible for the toxicity of GO on microbial communities. Deng et al. studied the characterization factors such as toxic effect factor, fate factor and exposure factor of GO in the environment to study the life cycle impact assessment of GO-based nanomaterials [159]. More research has to be conducted as there are very few studies on the environmental risks of GBNs and their strict enforcement on the release of GBNs to mitigate the toxic effects of GBNs. Lee et al. reported their findings on common scenarios (exfoliation, CVD growth and transfer) and the good practices that reduce graphene or GBNs exposure at facilities manufacturing facilities [68]. In addition to toxicity studies, GBNs especially three-dimensional (3D) porous carbon-based materials such as GO and GO-based networks have proven to have potential environmental applications. GBNs were explored for removing organic pollutants to advance in water remediation. Rethinsabapathy et al. summarized 3D GBNs materials used for the adsorption of dyes, heavy metals and radioactive materials from polluted environments [160].

6 Conclusions and Perspectives

It is evident that GBNs, because of their unique properties and functionalization, raise a great interest and provide more avenues for the research and development in their applications of translational medicine. The biomedical applications related to the unique physiochemical properties of GBNs focus on their thermal, mechanical and electrochemical features. Many reports have paid attention to GBNs as therapeutics in cancer therapy along with PTT and PDT, gene/drug delivery and as antibacterial agents. The intrinsic optical properties of GBN-based hybrids in the visible and NIR range along with their small size effects, low toxicity and low production costs make the hybrids attractive for bioimaging in clinical diagnostics and photo-thermal cancer therapy. This targeted therapy aids in their high therapeutic effects and fewer side effects. Among GBNs, GO and RGO are considered as the most potent antibacterial agents which can be used in nanohybrids to synthesize novel antibacterial agents. The use of GBNs in bioimaging and biosensing fields is an emerging biomedical application. As the GBNs are used in various fields for biomedical purposes the safety and efficacy of GBNs in clinical trials such as diagnostics and therapeutics require standardized parameters; mainly, biocompatibility, solubility and selectivity are the predominant factors that will further the biomedical applications of GBNs. More studies in computational simulations of GBNs need to be explored for the efficacy of GBNs in clinical trials.

The applications of GBNs have expanded quickly into various fields, but still, there is a lack of systematic understanding of biological interactions of GBNs. The experimental data on the toxicity are limited more to in vitro rather than to in vivo. In addition, there should be more knowledge of the long-term toxicity effects of GBNs to further enhance their applications in the biomedical field to assure the human safety. The existing literature does not provide detailed information on the various synthesis procedures and characterization techniques before proceeding to the toxicological assays. More emphasis should be given on the comprehensive understanding of GBNs-based products on adsorption, dispersion and toxicity, and transformation is recommended. Currently, most of the GBNs are focused on lungs and liver. Studies on other organs including brain/central nervous system are very limited or remain unexplored. Moreover, the GBNs due to excellent physicochemical properties can specifically disrupt the neuroendocrine/reproductive organs. To our knowledge, the reports on GBNs as endocrine disruptor are very limited. Additional studies in these areas are also necessary. Furthermore, GBNs can interact with DNA and thus affect the genetics of human populations. Therefore, studies are needed to elucidate transgenerational effects or effects of GBNs on the epigenome. Reina et al. emphasized the guidelines and the development and evaluation of biocompatibility of GBNs [29]. These guidelines include thorough characterization and regulatory standardization of GBNs, standardized data formats to identify the relationships between structure and properties and finally standard references of known activities of biological tests. Also, more research is required to optimize the synthesis with proper characterization methods to the GBNs with unique properties. The majority of research is on the toxicity at the cellular level rather than the interaction of GBNs at the genetic level. Since other GBNs such as 3D porous graphene materials have attracted great attention for environmental applications in the removal of pollutants of organic, inorganic and radionuclides [160], further studies are needed to evaluate their fate and transport as well as their ecological risks in various environmental compartments. Such research would provide a scientific basis to manage their uses and control/prevent their toxic effects.



This research was financially supported by National Institutes of Heath NIMHD Grant # G12MD007581 through the RCMI Center for Environmental Health and by National Science Foundation Grant # HRD-1547754 through the CREST Center for Nanotoxicity Studies at Jackson State University.


  1. 1.
    D.R. Dreyer, R.S. Ruoff, C.W. Bielawski, From conception to realization: an historical account of graphene and some perspectives for its future. Angew. Chem. Int. Edit. 49(49), 9336–9344 (2010). Google Scholar
  2. 2.
    G. Eda, M. Chhowalla, Graphene-based composite thin films for electronics. Nano Lett. 9(2), 814–818 (2009). Google Scholar
  3. 3.
    C. Cha, S.R. Shin, N. Annabi, M.R. Dokmeci, A. Khademhosseini, Carbon-based nanomaterials: multifunctional materials for biomedical engineering. ACS Nano 7(4), 2891–2897 (2013). Google Scholar
  4. 4.
    O.C. Compton, S.T. Nguyen, Graphene oxide, highly reduced graphene oxide, and graphene: versatile building blocks for carbon-based materials. Small 6(6), 711–723 (2010). Google Scholar
  5. 5.
    J. Wang, Carbon-nanotube based electrochemical biosensors: a review. Electroanalysis 17(1), 7–14 (2005). MathSciNetGoogle Scholar
  6. 6.
    M.S. Dresselhaus, P. Avouris, Introduction to carbon materials research. Top. Appl. Phys. 80, 1–9 (2001). Google Scholar
  7. 7.
    F.M.P. Tonelli, V.A.M. Goulart, K.N. Gomes, M.S. Ladeira, A.K. Santos, E. Lorençon, L.O. Ladeira, R.R. Resende, Graphene-based nanomaterials: biological and medical applications and toxicity. Nanomedicine 10(15), 2423–2450 (2015). Google Scholar
  8. 8.
    J.M. Yoo, J.H. Kang, B.H. Hong, Graphene-based nanomaterials for versatile imaging studies. Chem. Soc. Rev. 44(14), 4835–4852 (2015). Google Scholar
  9. 9.
    Y. Zhu, S. Murali, W. Cai, X. Li, J.W. Suk, J.R. Potts, R.S. Ruoff, Graphene and graphene oxide: synthesis, properties, and applications. Adv. Mater. 22(35), 3906–3924 (2010). Google Scholar
  10. 10.
    G. Bottari, M.Á. Herranz, L. Wibmer, M. Volland, L. Rodríguez-Pérez et al., Chemical functionalization and characterization of graphene-based materials. Chem. Soc. Rev. 46(15), 4464–4500 (2017). Google Scholar
  11. 11.
    T.-H. Kim, T. Lee, W. El-Said, J.-W. Choi, Graphene-based materials for stem cell applications. Materials 8(12), 8674–8690 (2015). Google Scholar
  12. 12.
    H. Ren, M. Tang, B. Guan, K. Wang, J. Yang et al., Hierarchical graphene foam for efficient omnidirectional solar-thermal energy conversion. Adv. Mater. 29(38), 1702590 (2017). Google Scholar
  13. 13.
    F. Liu, C.W. Lee, J.S. Im, Graphene-based carbon materials for electrochemical energy storage. J. Nanomater. 2013, 642915 (2013). Google Scholar
  14. 14.
    G. Gonçalves, P. Marques, M. Vila, Graphene-Based Materials in Health and Environment. Carbon Nanostructures (Springer, Switzerland, 2016). Google Scholar
  15. 15.
    S.S. Nanda, G.C. Papaefthymiou, D.K. Yi, Functionalization of graphene oxide and its biomedical applications. Crit. Rev. Solid State Mater. Sci. 40(5), 291–315 (2015). Google Scholar
  16. 16.
    L. Ou, B. Song, H. Liang, J. Liu, X. Feng, B. Deng, T. Sun, L. Shao, Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms. Part. Fibre Toxicol. 13(1), 57 (2016). Google Scholar
  17. 17.
    K.V. Krishna, C. Ménard-Moyon, S. Verma, A. Bianco, Graphene-based nanomaterials for nanobiotechnology and biomedical applications. Nanomedicine 8(10), 1669–1688 (2013). Google Scholar
  18. 18.
    C. Chung, Y.-K. Kim, D. Shin, S.-R. Ryoo, B.H. Hong, D.-H. Min, Biomedical applications of graphene and graphene oxide. Acc. Chem. Res. 46(10), 2211–2224 (2013). Google Scholar
  19. 19.
    Z.S. Singh, Applications and toxicity of graphene family nanomaterials and their composites. Nanotechnol. Sci. Appl. 2016(9), 15–28 (2016). Google Scholar
  20. 20.
    D.R. Dreyer, S. Park, C.W. Bielawski, R.S. Ruoff, The chemistry of graphene oxide. Chem. Soc. Rev. 39(1), 228–240 (2010). Google Scholar
  21. 21.
    P.R. Wallace, The band theory of graphite. Phys. Rev. 72(3), 258 (1947). zbMATHGoogle Scholar
  22. 22.
    K.S. Novoselov, Electric field effect in atomically thin carbon films. Science 306(5696), 666–669 (2004). Google Scholar
  23. 23.
    K. Muthoosamy, S. Manickam, State of the art and recent advances in the ultrasound-assisted synthesis, exfoliation and functionalization of graphene derivatives. Ultrason. Sonochem. 39(2017), 478–493 (2017). Google Scholar
  24. 24.
    G. Shim, M.-G. Kim, J.Y. Park, Y.-K. Oh, Graphene-based nanosheets for delivery of chemotherapeutics and biological drugs. Adv. Drug Deliver. Rev. 105, 205–227 (2016). Google Scholar
  25. 25.
    S. Pei, H.-M. Cheng, The reduction of graphene oxide. Carbon 50(9), 3210–3228 (2012). Google Scholar
  26. 26.
    H.C. Schniepp, J.L. Li, M.J. McAllister, H. Sai, M. Herrera-Alonso et al., Functionalized single graphene sheets derived from splitting graphite oxide. J. Phys. Chem. B 110(17), 8535–8539 (2006). Google Scholar
  27. 27.
    T. Kuila, S. Bose, A.K. Mishra, P. Khanra, N.H. Kim, J.H. Lee, Chemical functionalization of graphene and its applications. Prog. Mater Sci. 57(7), 1061–1105 (2012). Google Scholar
  28. 28.
    V. Georgakilas, J.N. Tiwari, K.C. Kemp, J.A. Perman, A.B. Bourlinos, K.S. Kim, R. Zboril, Noncovalent functionalization of graphene and graphene oxide for energy materials, biosensing, catalytic, and biomedical applications. Chem. Rev. 116(9), 5464–5519 (2016). Google Scholar
  29. 29.
    G. Reina, J.M. González-Domínguez, A. Criado, E. Vázquez, A. Bianco, M. Prato, Promises, facts and challenges for graphene in biomedical applications. Chem. Soc. Rev. 46(15), 4400–4416 (2017). Google Scholar
  30. 30.
    A. Jana, E. Scheer, S. Polarz, Synthesis of graphene–transition metal oxide hybrid nanoparticles and their application in various fields. Beilstein J. Nanotechnol. 8, 688–714 (2017). Google Scholar
  31. 31.
    K.E. Whitener, P.E. Sheehan, Graphene synthesis. Diam. Relat. Mater. 46, 25–34 (2014). Google Scholar
  32. 32.
    J. Xu, Y. Wang, S. Hu, Nanocomposites of graphene and graphene oxides: synthesis, molecular functionalization and application in electrochemical sensors and biosensors. A review. Microchim. Acta 184(1), 1–44 (2016). Google Scholar
  33. 33.
    J. Lin, X. Chen, P. Huang, Graphene-based nanomaterials for bioimaging. Adv. Drug Deliver. Rev. 105, 242–254 (2016). Google Scholar
  34. 34.
    P. Huang, S. Wang, X. Wang, G. Shen, J. Lin et al., Surface functionalization of chemically reduced graphene oxide for targeted photodynamic therapy. J. Biomed. Nanotechnol. 11(1), 117–125 (2015). Google Scholar
  35. 35.
    X. Huang, F. Boey, H.U.A. Zhang, A brief review on graphene-nanoparticle composites. Cosmos 06(02), 159–166 (2010). Google Scholar
  36. 36.
    M. Agharkar, S. Kochrekar, S. Hidouri, M.A. Azeez, Trends in green reduction of graphene oxides, issues and challenges: a review. Mater. Res. Bull. 59, 323–328 (2014). Google Scholar
  37. 37.
    S. Thakur, N. Karak, Alternative methods and nature-based reagents for the reduction of graphene oxide: a review. Carbon 94, 224–242 (2015). Google Scholar
  38. 38.
    H. Zhang, G. Grüner, Y. Zhao, Recent advancements of graphene in biomedicine. J. Mater. Chem. B 2013(1), 2542–2567 (2013). Google Scholar
  39. 39.
    T.-H. Han, H. Kim, S.-J. Kwon, T.-W. Lee, Graphene-based flexible electronic devices. Mater. Sci. Eng., R 118, 1–43 (2017). Google Scholar
  40. 40.
    H. Jang, Y.J. Park, X. Chen, T. Das, M.-S. Kim, J.-H. Ahn, Graphene-based flexible and stretchable electronics. Adv. Mater. 28(22), 4184–4202 (2016). Google Scholar
  41. 41.
    K. Yang, L. Feng, H. Hong, W. Cai, Z. Liu, Preparation and functionalization of graphene nanocomposites for biomedical applications. Nat. Protoc. 8(12), 2392–2403 (2013). Google Scholar
  42. 42.
    J. Liu, L. Cui, D. Losic, Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater. 9(12), 9243–9257 (2013). Google Scholar
  43. 43.
    D.W. Boukhvalov, M.I. Katsnelson, Modeling of graphite oxide. J. Am. Chem. Soc. 130(32), 10697–10701 (2008). Google Scholar
  44. 44.
    S.-E. Zhu, M. Krishna Ghatkesar, C. Zhang, G.C.A.M. Janssen, Graphene based piezoresistive pressure sensor. Appl. Phys. Lett. 102(16), 161904 (2013). Google Scholar
  45. 45.
    Y. Yang, A.M. Asiri, Z. Tang, D. Du, Y. Lin, Graphene based materials for biomedical applications. Mater. Today 16(10), 365–373 (2013). Google Scholar
  46. 46.
    M. Nurunnabi, K. Parvez, M. Nafiujjaman, V. Revuri, H.A. Khan, X. Feng, Y.-K. Lee, Bioapplication of graphene oxide derivatives: drug/gene delivery, imaging, polymeric modification, toxicology, therapeutics and challenges. RSC Adv. 5(52), 42141–42161 (2015). Google Scholar
  47. 47.
    K. Yang, L. Feng, X. Shi, Z. Liu, Nano-graphene in biomedicine: theranostic applications. Chem. Soc. Rev. 42(2), 530–547 (2013). Google Scholar
  48. 48.
    K. Yang, H. Gong, X. Shi, J. Wan, Y. Zhang, Z. Liu, In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration. Biomaterials 34(11), 2787–2795 (2013). Google Scholar
  49. 49.
    T.L. Moore, R. Podilakrishna, A. Rao, F. Alexis, Systemic administration of polymer-coated nano-graphene to deliver drugs to glioblastoma. Part. Part. Syst. Charact. 31(8), 886–894 (2014). Google Scholar
  50. 50.
    S.M. Chowdhury, C. Surhland, Z. Sanchez, P. Chaudhary, M.A. Suresh Kumar et al., Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme. Nanomed. Nanotechnol. Biol. Med. 11(1), 109–118 (2015). Google Scholar
  51. 51.
    X. Sun, Z. Liu, K. Welsher, J.T. Robinson, A. Goodwin, S. Zaric, H. Dai, Nano-graphene oxide for cellular imaging and drug delivery. Nano Res. 1(3), 203–212 (2008). Google Scholar
  52. 52.
    Nayak EbPK, Recent advances in graphene research (InTech; 2016).
  53. 53.
    H. Wu, W. Lu, J.-J. Shao, C. Zhang, M.-B. Wu, B.-H. Li, Q.-H. Yang, Ph-dependent size, surface chemistry and electrochemical properties of graphene oxide. Carbon 67, 795 (2014). Google Scholar
  54. 54.
    V.K. Rana, M.-C. Choi, J.-Y. Kong, G.Y. Kim, M.J. Kim, S.-H. Kim, S. Mishra, R.P. Singh, C.-S. Ha, Synthesis and drug-delivery behavior of chitosan-functionalized graphene oxide hybrid nanosheets. Macromol. Mater. Eng. 296(2), 131–140 (2010). Google Scholar
  55. 55.
    R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016. CA-Cancer J. Clin. 66(1), 7–30 (2016). Google Scholar
  56. 56.
    R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2017. CA-Cancer J. Clin. 67(1), 7–30 (2017). Google Scholar
  57. 57.
    L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J.T. Johnson, T.L. Whiteside, A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor- 1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 13(15), 4345–4354 (2007). Google Scholar
  58. 58.
    J.A. Burger, Cxcr4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5), 1761–1767 (2006). Google Scholar
  59. 59.
    M. Bissell, M. Labarge, Context, tissue plasticity, and cancerare tumor stem cells also regulated by the microenvironment? Cancer Cell 7(1), 17–23 (2005). Google Scholar
  60. 60.
    K. Kessenbrock, V. Plaks, Z. Werb, Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1), 52–67 (2010). Google Scholar
  61. 61.
    L. Zhang, J. Xia, Q. Zhao, L. Liu, Z. Zhang, Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small 6(4), 537–544 (2010). Google Scholar
  62. 62.
    B. Adhikari, A. Biswas, A. Banerjee, Graphene oxide-based hydrogels to make metal nanoparticle-containing reduced graphene oxide-based functional hybrid hydrogels. ACS Appl. Mater. Interfaces. 4(10), 5472–5482 (2012). Google Scholar
  63. 63.
    W. Zhang, Z. Guo, D. Huang, Z. Liu, X. Guo, H. Zhong, Synergistic effect of chemo-photothermal therapy using pegylated graphene oxide. Biomaterials 32(33), 8555–8561 (2011). Google Scholar
  64. 64.
    Y.-W. Chen, Y.-L. Su, S.-H. Hu, S.-Y. Chen, Functionalized graphene nanocomposites for enhancing photothermal therapy in tumor treatment. Adv. Drug Deliver. Rev. 105, 190–204 (2016). Google Scholar
  65. 65.
    L. Liu, J. Zhang, J. Zhao, F. Liu, Mechanical properties of graphene oxides. Nanoscale 4(19), 5910–5916 (2012). Google Scholar
  66. 66.
    X. Bian, Z.-L. Song, Y. Qian, W. Gao, Z.-Q. Cheng et al., Fabrication of graphene-isolated-au-nanocrystal nanostructures for multimodal cell imaging and photothermal-enhanced chemotherapy. Sci. Rep. 4(1), 6093 (2014). Google Scholar
  67. 67.
    C. Yao, L. Zhang, J. Wang, Y. He, J. Xin, S. Wang, H. Xu, Z. Zhang, Gold nanoparticle mediated phototherapy for cancer. J. Nanomater. 2016, 5497136 (2016). Google Scholar
  68. 68.
    Y.-H. Lee, Y.-H. Lai, Synthesis, characterization, and biological evaluation of anti-her2 indocyanine green-encapsulated peg-coated plga nanoparticles for targeted phototherapy of breast cancer cells. PLoS ONE 11(12), e0168192 (2016). Google Scholar
  69. 69.
    L. Cheng, C. Wang, L. Feng, K. Yang, Z. Liu, Functional nanomaterials for phototherapies of cancer. Chem. Rev. 114(21), 10869–10939 (2014). Google Scholar
  70. 70.
    U. Chitgupi, Y. Qin, J.F. Lovell, Targeted nanomaterials for phototherapy. Nanotheranostics 1(1), 38–58 (2017). Google Scholar
  71. 71.
    E. Paszko, C. Ehrhardt, M.O. Senge, D.P. Kelleher, J.V. Reynolds, Nanodrug applications in photodynamic therapy. Photodiagn. Photodyn. 8(1), 14–29 (2011). Google Scholar
  72. 72.
    D.K. Chatterjee, L.S. Fong, Y. Zhang, Nanoparticles in photodynamic therapy: an emerging paradigm. Adv. Drug Deliver. Rev. 60(15), 1627–1637 (2008). Google Scholar
  73. 73.
    S. Shi, F. Chen, E.B. Ehlerding, W. Cai, Surface engineering of graphene-based nanomaterials for biomedical applications. Bioconjug. Chem. 25(9), 1609–1619 (2014). Google Scholar
  74. 74.
    B. Zhang, Y. Wang, G. Zhai, Biomedical applications of the graphene-based materials. Mater. Sci. Eng., C 61, 953–964 (2016). Google Scholar
  75. 75.
    R. Kurapati, K. Kostarelos, M. Prato, A. Bianco, Biomedical uses for 2D materials beyond graphene: current advances and challenges ahead. Adv. Mater. 28, 6052–6074 (2016). Google Scholar
  76. 76.
    N. Rahmanian, H. Hamishehkar, J.E.N. Dolatabadi, N. Arsalani, Nano graphene oxide: a novel carrier for oral delivery of flavonoids. Colloid Surfaces B 123, 331–338 (2014). Google Scholar
  77. 77.
    Z. Liu, J.T. Robinson, S.M. Tabakman, K. Yang, H. Dai, Carbon materials for drug delivery & cancer therapy. Mater. Today 14(7–8), 316–323 (2011). Google Scholar
  78. 78.
    S. Some, A.R. Gwon, E. Hwang, G.-H. Bahn, Y. Yoon et al., Cancer therapy using ultrahigh hydrophobic drug-loaded graphene derivatives. Sci. Rep. 4(1), 6314 (2014). Google Scholar
  79. 79.
    X. Wang, X. Sun, J. Lao, H. He, T. Cheng, M. Wang, S. Wang, F. Huang, Multifunctional graphene quantum dots for simultaneous targeted cellular imaging and drug delivery. Colloid Surfaces B 122, 638–644 (2014). Google Scholar
  80. 80.
    B. Tian, C. Wang, S. Zhang, L. Feng, Z. Liu, Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide. ACS Nano 5(9), 7000–7009 (2011). Google Scholar
  81. 81.
    C. Xu, D. Yang, L. Mei, Q. Li, H. Zhu, T. Wang, Targeting chemophotothermal therapy of hepatoma by gold nanorods/graphene oxide core/shell nanocomposites. ACS Appl. Mater. Interfaces. 5(24), 12911–12920 (2013). Google Scholar
  82. 82.
    U. Dembereldorj, S.Y. Choi, E.-O. Ganbold, N.W. Song, D. Kim, J. Choo, S.Y. Lee, S. Kim, S.-W. Joo, Gold nanorod-assembled pegylated graphene-oxide nanocomposites for photothermal cancer therapy. Photochem. Photobiol. 90(3), 659–666 (2013). Google Scholar
  83. 83.
    C. Wang, J. Mallela, U.S. Garapati, S. Ravi, V. Chinnasamy, Y. Girard, M. Howell, S. Mohapatra, A chitosan-modified graphene nanogel for noninvasive controlled drug release. Nanomed. Nanotechnol. Biol. Med. 9(7), 903–911 (2013). Google Scholar
  84. 84.
    Y. Jin, J. Wang, H. Ke, S. Wang, Z. Dai, Graphene oxide modified pla microcapsules containing gold nanoparticles for ultrasonic/ct bimodal imaging guided photothermal tumor therapy. Biomaterials 34(20), 4794–4802 (2013). Google Scholar
  85. 85.
    L. Feng, K. Li, X. Shi, M. Gao, J. Liu, Z. Liu, Smart ph-responsive nanocarriers based on nano-graphene oxide for combined chemo- and photothermal therapy overcoming drug resistance. Adv. Healthc. Mater. 3(8), 1261–1271 (2014). Google Scholar
  86. 86.
    B.P. Viraka Nellore, A. Pramanik, S.R. Chavva, S.S. Sinha, C. Robinson et al., Aptamer-conjugated theranostic hybrid graphene oxide with highly selective biosensing and combined therapy capability. Faraday Discuss. 175, 257–271 (2014). Google Scholar
  87. 87.
    D. Hu, J. Zhang, G. Gao, Z. Sheng, H. Cui, L. Cai, Indocyanine green-loaded polydopamine-reduced graphene oxide nanocomposites with amplifying photoacoustic and photothermal effects for cancer theranostics. Theranostics 6(7), 1043–1052 (2016). Google Scholar
  88. 88.
    J. Li, S. Tan, R. Kooger, C. Zhang, Y. Zhang, Micrornas as novel biological targets for detection and regulation. Chem. Soc. Rev. 43(2), 506–517 (2014). Google Scholar
  89. 89.
    A. Paul, A. Hasan, H.A. Kindi, A.K. Gaharwar, V.T.S. Rao et al., Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano 8(8), 8050–8062 (2014). Google Scholar
  90. 90.
    L. Feng, X. Yang, X. Shi, X. Tan, R. Peng, J. Wang, Z. Liu, Polyethylene glycol and polyethylenimine dual-functionalized nano-graphene oxide for photothermally enhanced gene delivery. Small 9(11), 1989–1997 (2013). Google Scholar
  91. 91.
    T. Niidome, L. Huang, Gene therapy progress and prospects: nonviral vectors. Gene Ther. 9(24), 1647–1652 (2002). Google Scholar
  92. 92.
    R. Waehler, S.J. Russell, D.T. Curiel, Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8(8), 573–587 (2007). Google Scholar
  93. 93.
    H. Bao, Y. Pan, Y. Ping, N.G. Sahoo, T. Wu, L. Li, J. Li, L.H. Gan, Chitosan-functionalized graphene oxide as a nanocarrier for drug and gene delivery. Small 7(11), 1569–1578 (2011). Google Scholar
  94. 94.
    H. Kim, D. Lee, J. Kim, T.-I. Kim, W.J. Kim, Photothermally triggered cytosolic drug delivery via endosome disruption using a functionalized reduced graphene oxide. ACS Nano 7(8), 6735–6746 (2013). Google Scholar
  95. 95.
    H. Kim, W.J. Kim, Photothermally controlled gene delivery by reduced graphene oxide-polyethylenimine nanocomposite. Small 10(1), 117–126 (2013). Google Scholar
  96. 96.
    T. Sandle, Antibiotic/antimicrobial resistance, in The Sage Encyclopedia of Pharmacology and Society, ed. by S. Boslaugh (Sage, Thousand Oaks, 2016)Google Scholar
  97. 97.
    A.M. Allahverdiyev, K.V. Kon, E.S. Abamor, M. Bagirova, M. Rafailovich, Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert Rev. Anti-infe. 9(11), 1035–1052 (2011). Google Scholar
  98. 98.
    W. Hu, C. Peng, W. Luo, M. Lv, X. Li, D. Li, Q. Huang, C. Fan, Graphene-based antibacterial paper. ACS Nano 4(7), 4317–4323 (2010). Google Scholar
  99. 99.
    Y. Tu, M. Lv, P. Xiu, T. Huynh, M. Zhang et al., Destructive extraction of phospholipids from escherichia coli membranes by graphene nanosheets. Nat. Nanotechnol. 8(8), 594–601 (2013). Google Scholar
  100. 100.
    S. Liu, M. Hu, T.H. Zeng, R. Wu, R. Jiang, J. Wei, L. Wang, J. Kong, Y. Chen, Lateral dimension-dependent antibacterial activity of graphene oxide sheets. Langmuir 28(33), 12364–12372 (2012). Google Scholar
  101. 101.
    M.-C. Wu, A.R. Deokar, J.-H. Liao, P.-Y. Shih, Y.-C. Ling, Graphene-based photothermal agent for rapid and effective killing of bacteria. ACS Nano 7(2), 1281–1290 (2013). Google Scholar
  102. 102.
    S. Gurunathan, J. Woong Han, A. Abdal Daye, V. Eppakayala, J.-H. Kim, Oxidative stress-mediated antibacterial activity of graphene oxide and reduced graphene oxide in pseudomonas aeruginosa. Int. J. Nanomed. 7, 5901–5914 (2012). Google Scholar
  103. 103.
    I. Ocsoy, M.L. Paret, M.A. Ocsoy, S. Kunwar, T. Chen, M. You, W. Tan, Nanotechnology in plant disease management: DNA-directed silver nanoparticles on graphene oxide as an antibacterial against xanthomonas perforans. ACS Nano 7(10), 8972–8980 (2013). Google Scholar
  104. 104.
    C. Li, X. Wang, F. Chen, C. Zhang, X. Zhi, K. Wang, D. Cui, The antifungal activity of graphene oxide–silver nanocomposites. Biomaterials 34(15), 3882–3890 (2013). Google Scholar
  105. 105.
    Y. Ouyang, X. Cai, Q. Shi, L. Liu, D. Wan, S. Tan, Y. Ouyang, Poly-l-lysine-modified reduced graphene oxide stabilizes the copper nanoparticles with higher water-solubility and long-term additively antibacterial activity. Colloid Surfaces B 107, 107–114 (2013). Google Scholar
  106. 106.
    N. Hussain, A. Gogoi, R.K. Sarma, P. Sharma, A. Barras, R. Boukherroub, R. Saikia, P. Sengupta, M.R. Das, Reduced graphene oxide nanosheets decorated with au nanoparticles as an effective bactericide: investigation of biocompatibility and leakage of sugars and proteins. ChemPlusChem 79(12), 1774–1784 (2014). Google Scholar
  107. 107.
    O. Akhavan, E. Ghaderi, Photocatalytic reduction of graphene oxide nanosheets on TiO2 thin film for photoinactivation of bacteria in solar light irradiation. J. Phys. Chem. C 113(47), 20214–20220 (2009). Google Scholar
  108. 108.
    Y.-W. Wang, A. Cao, Y. Jiang, X. Zhang, J.-H. Liu, Y. Liu, H. Wang, Superior antibacterial activity of zinc oxide/graphene oxide composites originating from high zinc concentration localized around bacteria. ACS Appl. Mater. Interfaces. 6(4), 2791–2798 (2014). Google Scholar
  109. 109.
    I.E. Mejías Carpio, C.M. Santos, X. Wei, D.F. Rodrigues, Toxicity of a polymer–graphene oxide composite against bacterial planktonic cells, biofilms, and mammalian cells. Nanoscale 4(15), 4746–4756 (2012). Google Scholar
  110. 110.
    S. Some, S.-M. Ho, P. Dua, E. Hwang, Y.H. Shin, H. Yoo, J.-S. Kang, D.-K. Lee, H. Lee, Dual functions of highly potent graphene derivative–poly-l-lysine composites to inhibit bacteria and support human cells. ACS Nano 6(8), 7151–7161 (2012). Google Scholar
  111. 111.
    J. Tang, Q. Chen, L. Xu, S. Zhang, L. Feng, L. Cheng, H. Xu, Z. Liu, R. Peng, Graphene oxide–silver nanocomposite as a highly effective antibacterial agent with species-specific mechanisms. ACS Appl. Mater. Interfaces. 5(9), 3867–3874 (2013). Google Scholar
  112. 112.
    Z. Fan, B. Liu, J. Wang, S. Zhang, Q. Lin, P. Gong, L. Ma, S. Yang, A novel wound dressing based on ag/graphene polymer hydrogel: effectively kill bacteria and accelerate wound healing. Adv. Funct. Mater. 24(25), 3933–3943 (2014). Google Scholar
  113. 113.
    B. Lu, T. Li, H. Zhao, X. Li, C. Gao, S. Zhang, E. Xie, Graphene-based composite materials beneficial to wound healing. Nanoscale 4(9), 2978–2982 (2012). Google Scholar
  114. 114.
    S.R. Shin, Y.-C. Li, H.L. Jang, P. Khoshakhlagh, M. Akbari, A. Nasajpour, Y.S. Zhang, A. Tamayol, A. Khademhosseini, Graphene-based materials for tissue engineering. Adv. Drug Deliver. Rev. 105, 255–274 (2016). Google Scholar
  115. 115.
    O. Akhavan, Graphene scaffolds in progressive nanotechnology/stem cell-based tissue engineering of the nervous system. J. Mater. Chem. B 4(19), 3169–3190 (2016). Google Scholar
  116. 116.
    A.L. Rutz, K.E. Hyland, A.E. Jakus, W.R. Burghardt, R.N. Shah, A multimaterial bioink method for 3d printing tunable, cell-compatible hydrogels. Adv. Mater. 27(9), 1607–1614 (2015). Google Scholar
  117. 117.
    S. Seethamraju, S. Kumar, K.B. Bharadwaj, G. Madras, S. Raghavan, P.C. Ramamurthy, Million-fold decrease in polymer moisture permeability by a graphene monolayer. ACS Nano 10(7), 6501–6509 (2016). Google Scholar
  118. 118.
    S. Goenka, V. Sant, S. Sant, Graphene-based nanomaterials for drug delivery and tissue engineering. J. Control. Release 173, 75–88 (2014). Google Scholar
  119. 119.
    J. Abraham, K.S. Vasu, C.D. Williams, K. Gopinadhan, Y. Su et al., Tunable sieving of ions using graphene oxide membranes. Nat. Nanotechnol. 12(6), 546–550 (2017). Google Scholar
  120. 120.
    H.M. Hegab, A. ElMekawy, L. Zou, D. Mulcahy, C.P. Saint, M. Ginic-Markovic, The controversial antibacterial activity of graphene-based materials. Carbon 105, 362–376 (2016). Google Scholar
  121. 121.
    H. Ji, H. Sun, X. Qu, Antibacterial applications of graphene-based nanomaterials: recent achievements and challenges. Adv. Drug Deliver. Rev. 105, 176–189 (2016). Google Scholar
  122. 122.
    J. Zhao, Z. Wang, J.C. White, B. Xing, Graphene in the aquatic environment: adsorption, dispersion, toxicity and transformation. Environ. Sci. Technol. 48(17), 9995–10009 (2014). Google Scholar
  123. 123.
    M.E. Foo, S.C.B. Gopinath, Feasibility of graphene in biomedical applications. Biomed. Pharmacother. 94, 354–361 (2017). Google Scholar
  124. 124.
    P. Wu, Y. Qian, P. Du, H. Zhang, C. Cai, Facile synthesis of nitrogen-doped graphene for measuring the releasing process of hydrogen peroxide from living cells. J. Mater. Chem. 22(13), 6402–6412 (2012). Google Scholar
  125. 125.
    X. Kang, J. Wang, H. Wu, I.A. Aksay, J. Liu, Y. Lin, Glucose oxidase–graphene–chitosan modified electrode for direct electrochemistry and glucose sensing. Biosens. Bioelectron. 25(4), 901–905 (2009). Google Scholar
  126. 126.
    L. Jiang, Y. Liu, S. Liu, G. Zeng, X. Hu et al., Adsorption of estrogen contaminants by graphene nanomaterials under natural organic matter preloading: comparison to carbon nanotube, biochar, and activated carbon. Environ. Sci. Technol. 51(11), 6352–6359 (2017). Google Scholar
  127. 127.
    L. Tang, Y. Wang, Y. Li, H. Feng, J. Lu, J. Li, Preparation, structure, and electrochemical properties of reduced graphene sheet films. Adv. Funct. Mater. 19(17), 2782–2789 (2009). Google Scholar
  128. 128.
    D. Chen, H. Feng, J. Li, Graphene oxide: preparation, functionalization, and electrochemical applications. Chem. Rev. 112(11), 6027–6053 (2012). Google Scholar
  129. 129.
    D. Lin, J. Wu, H. Ju, F. Yan, Nanogold/mesoporous carbon foam-mediated silver enhancement for graphene-enhanced electrochemical immunosensing of carcinoembryonic antigen. Biosens. Bioelectron. 52, 153–158 (2014). Google Scholar
  130. 130.
    B. Liu, D. Tang, J. Tang, B. Su, Q. Li, G. Chen, A graphene-based au(111) platform for electrochemical biosensing based catalytic recycling of products on gold nanoflowers. Analyst 136(11), 2218–2220 (2011). Google Scholar
  131. 131.
    K.T. Nguyen, Y. Zhao, Integrated graphene/nanoparticle hybrids for biological and electronic applications. Nanoscale 6(12), 6245–6266 (2014). Google Scholar
  132. 132.
    J. Tian, T. Huang, P. Wang, J. Lu, God/hrp bienzyme synergistic catalysis in a 2-D graphene framework for glucose biosensing. J. Electrochem. Soc. 162(12), B319–B325 (2015). Google Scholar
  133. 133.
    C. Shan, H. Yang, D. Han, Q. Zhang, A. Ivaska, L. Niu, Graphene/AuNPs/chitosan nanocomposites film for glucose biosensing. Biosens. Bioelectron. 25(5), 1070–1074 (2010). Google Scholar
  134. 134.
    P. Song, X. Zhang, M. Sun, X. Cui, Y. Lin, Graphene oxide modified TiO2 nanotube arrays: enhanced visible light photoelectrochemical properties. Nanoscale 4(5), 1800 (2012). Google Scholar
  135. 135.
    X. Wu, S.-J. Ding, K. Lin, J. Su, A review on the biocompatibility and potential applications of graphene in inducing cell differentiation and tissue regeneration. J. Mater. Chem. B 5(17), 3084–3102 (2017). Google Scholar
  136. 136.
    V. Poornima Parvathi, M. Umadevi, R. Bhaviya Raj, Improved waste water treatment by bio-synthesized graphene sand composite. J. Environ. Manag. 162, 299–305 (2015). Google Scholar
  137. 137.
    A. El-Fiqi, J.H. Lee, E.-J. Lee, H.-W. Kim, Collagen hydrogels incorporated with surface-aminated mesoporous nanobioactive glass: improvement of physicochemical stability and mechanical properties is effective for hard tissue engineering. Acta Biomater. 9(12), 9508–9521 (2013). Google Scholar
  138. 138.
    V. Rosa, Z. Zhang, R.H.M. Grande, J.E. Nör, Dental pulp tissue engineering in full-length human root canals. J. Dent. Res. 92(11), 970–975 (2013). Google Scholar
  139. 139.
    L. Qiu, J.Z. Liu, S.L.Y. Chang, Y. Wu, D. Li, Biomimetic superelastic graphene-based cellular monoliths. Nat. Commun. 3, 1241 (2012). Google Scholar
  140. 140.
    L. Wang, C. Lu, B. Zhang, B. Zhao, F. Wu, S. Guan, Fabrication and characterization of flexible silk fibroin films reinforced with graphene oxide for biomedical applications. RSC Adv. 4(76), 40312–40320 (2014). Google Scholar
  141. 141.
    D. Li, T. Liu, X. Yu, D. Wu, Z. Su, Fabrication of graphene-biomacromolecule hybrid materials for tissue engineering application. Polym. Chem. 8(30), 4309–4321 (2017). Google Scholar
  142. 142.
    T.R. Nayak, H. Andersen, V.S. Makam, C. Khaw, S. Bae et al., Graphene for controlled and accelerated osteogenic differentiation of human mesenchymal stem cells. ACS Nano 5(6), 4670–4678 (2011). Google Scholar
  143. 143.
    S.Y. Park, J. Park, S.H. Sim, M.G. Sung, K.S. Kim, B.H. Hong, S. Hong, Enhanced differentiation of human neural stem cells into neurons on graphene. Adv. Mater. 23(36), H263–H267 (2011). Google Scholar
  144. 144.
    G. Nasim, G. Hamidreza, K. Mahshid, F. Mohammadhossein, A facile one-step strategy for development of a double network fibrous scaffold for nerve tissue engineering. Biofabrication 9(2), 025008 (2017). Google Scholar
  145. 145.
    M. Zhou, Y. Zhai, S. Dong, Electrochemical sensing and biosensing platform based on chemically reduced graphene oxide. Anal. Chem. 81(14), 5603–5613 (2009). Google Scholar
  146. 146.
    S. Park, J. An, I. Jung, R.D. Piner, S.J. An, X. Li, A. Velamakanni, R.S. Ruoff, Colloidal suspensions of highly reduced graphene oxide in a wide variety of organic solvents. Nano Lett. 9(4), 1593–1597 (2009). Google Scholar
  147. 147.
    A. Bianco, Graphene: safe or toxic? The two faces of the medal. Angew. Chem. Int. Edit. 52(19), 4986–4997 (2013). Google Scholar
  148. 148.
    C. McCallion, J. Burthem, K. Rees-Unwin, A. Golovanov, A. Pluen, Graphene in therapeutics delivery: problems, solutions and future opportunities. Eur. J. Pharm. Biopharm. 104, 235–250 (2016). Google Scholar
  149. 149.
    E. Mahmoudi, L.Y. Ng, M.M. Ba-Abbad, A.W. Mohammad, Novel nanohybrid polysulfone membrane embedded with silver nanoparticles on graphene oxide nanoplates. Chem. Eng. J. 277, 1–10 (2015). Google Scholar
  150. 150.
    V.C. Sanchez, A. Jachak, R.H. Hurt, A.B. Kane, Biological interactions of graphene-family nanomaterials: an interdisciplinary review. Chem. Res. Toxicol. 25(1), 15–34 (2012). Google Scholar
  151. 151.
    S. Syama, P.V. Mohanan, Safety and biocompatibility of graphene: a new generation nanomaterial for biomedical application. Int. J. Biol. Macromol. 86, 546–555 (2016). Google Scholar
  152. 152.
    B. Zhang, P. Wei, Z. Zhou, T. Wei, Interactions of graphene with mammalian cells: molecular mechanisms and biomedical insights. Adv. Drug Deliver. Rev. 105, 145–162 (2016). Google Scholar
  153. 153.
    I. Chowdhury, M.C. Duch, N.D. Mansukhani, M.C. Hersam, D. Bouchard, Colloidal properties and stability of graphene oxide nanomaterials in the aquatic environment. Environ. Sci. Technol. 47(12), 6288–6296 (2013). Google Scholar
  154. 154.
    I. Chowdhury, M.C. Duch, N.D. Mansukhani, M.C. Hersam, D. Bouchard, Interactions of graphene oxide nanomaterials with natural organic matter and metal oxide surfaces. Environ. Sci. Technol. 48(16), 9382–9390 (2014). Google Scholar
  155. 155.
    I. Chowdhury, W.-C. Hou, D. Goodwin, M. Henderson, R.G. Zepp, D. Bouchard, Sunlight affects aggregation and deposition of graphene oxide in the aquatic environment. Water Res. 78, 37–46 (2015). Google Scholar
  156. 156.
    L. Wu, L. Liu, B. Gao, R. Muñoz-Carpena, M. Zhang, H. Chen, Z. Zhou, H. Wang, Aggregation kinetics of graphene oxides in aqueous solutions: experiments, mechanisms, and modeling. Langmuir 29(49), 15174–15181 (2013). Google Scholar
  157. 157.
    Z. Hua, Z. Tang, X. Bai, J. Zhang, L. Yu, H. Cheng, Aggregation and resuspension of graphene oxide in simulated natural surface aquatic environments. Environ. Pollut. 205, 161–169 (2015). Google Scholar
  158. 158.
    F. Ahmed, D.F. Rodrigues, Investigation of acute effects of graphene oxide on wastewater microbial community: a case study. J. Hazard. Mater. 256–257, 33–39 (2013). Google Scholar
  159. 159.
    Y. Deng, J. Li, M. Qiu, F. Yang, J. Zhang, C. Yuan, Deriving characterization factors on freshwater ecotoxicity of graphene oxide nanomaterial for life cycle impact assessment. Int. J. Life Cycle Ass. 22(2), 222–236 (2016). Google Scholar
  160. 160.
    M. Rethinasabapathy, S.-M. Kang, S.-C. Jang, Y.S. Huh, Three-dimensional porous graphene materials for environmental applications. Carbon lett 22, 1–13 (2017). Google Scholar
  161. 161.
    X. Zou, L. Zhang, Z. Wang, Y. Luo, Mechanisms of the antimicrobial activities of graphene materials. J. Am. Chem. Soc. 138(7), 2064–2077 (2016). Google Scholar
  162. 162.
    J. Wu, Y.-S. Wang, X.-Y. Yang, Y.-Y. Liu, J.-R. Yang, R. Yang, N. Zhang, Graphene oxide used as a carrier for adriamycin can reverse drug resistance in breast cancer cells. Nanotechnology 23(35), 355101 (2012). Google Scholar
  163. 163.
    D. Ma, J. Lin, Y. Chen, W. Xue, L.-M. Zhang, In situ gelation and sustained release of an antitumor drug by graphene oxide nanosheets. Carbon 50(8), 3001–3007 (2012). Google Scholar
  164. 164.
    U. Dembereldorj, M. Kim, S. Kim, E.-O. Ganbold, S.Y. Lee, S.-W. Joo, A spatiotemporal anticancer drug release platform of pegylated graphene oxide triggered by glutathione in vitro and in vivo. J. Mater. Chem. 22(45), 23845–23851 (2012). Google Scholar
  165. 165.
    H. Wen, C. Dong, H. Dong, A. Shen, W. Xia et al., Engineered redox-responsive peg detachment mechanism in pegylated nano-graphene oxide for intracellular drug delivery. Small 8(5), 760–769 (2012). Google Scholar
  166. 166.
    T. Zhou, X. Zhou, D. Xing, Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarrier. Biomaterials 35(13), 4185–4194 (2014). Google Scholar
  167. 167.
    C. Wang, J. Li, C. Amatore, Y. Chen, H. Jiang, X.-M. Wang, Gold nanoclusters and graphene nanocomposites for drug delivery and imaging of cancer cells. Angew. Chem. Int. Edit. 50(49), 11644–11648 (2011). Google Scholar
  168. 168.
    Y. Pan, H. Bao, N.G. Sahoo, T. Wu, L. Li, Water-soluble poly(n-isopropylacrylamide)-graphene sheets synthesized via click chemistry for drug delivery. Adv. Funct. Mater. 21(14), 2754–2763 (2011). Google Scholar
  169. 169.
    T. Kavitha, I.-K. Kang, S.-Y. Park, Poly(n-vinyl caprolactam) grown on nanographene oxide as an effective nanocargo for drug delivery. Colloid Surfaces B 115, 37–45 (2014). Google Scholar
  170. 170.
    N.G. Sahoo, H. Bao, Y. Pan, M. Pal, M. Kakran, H.K.F. Cheng, L. Li, L.P. Tan, Functionalized carbon nanomaterials as nanocarriers for loading and delivery of a poorly water-soluble anticancer drug: a comparative study. Chem. Commun. 47(18), 5235–5237 (2011). Google Scholar
  171. 171.
    K. Liu, Y. Wang, H. Li, Y. Duan, A facile one-pot synthesis of starch functionalized graphene as nano-carrier for ph sensitive and starch-mediated drug delivery. Colloid Surfaces B 128, 86–93 (2015). Google Scholar
  172. 172.
    A. Angelopoulou, E. Voulgari, E.K. Diamanti, D. Gournis, K. Avgoustakis, Graphene oxide stabilized by pla–peg copolymers for the controlled delivery of paclitaxel. Eur. J. Pharm. Biopharm. 93, 18–26 (2015). Google Scholar
  173. 173.
    J. Li, Z. Lyv, Y. Li, H. Liu, J. Wang, W. Zhan, H. Chen, H. Chen, X. Li, A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug. Biomaterials 51, 12–21 (2015). Google Scholar
  174. 174.
    J. An, Y. Gou, C. Yang, F. Hu, C. Wang, Synthesis of a biocompatible gelatin functionalized graphene nanosheets and its application for drug delivery. Mater. Sci. Eng., C 33(5), 2827–2837 (2013). Google Scholar
  175. 175.
    J.-P. Chen, Y.-J. Lu, S.-C. Hung, J.-P. Chen, K.-C. Wei, Improving thermal stability and efficacy of bcnu in treating glioma cells using paa-functionalized graphene oxide. Int. J. Nanomed. 2012(7), 1737–1747 (2012). Google Scholar
  176. 176.
    X. Fan, G. Jiao, W. Zhao, P. Jin, X. Li, Magnetic Fe3O4–graphene composites as targeted drug nanocarriers for ph-activated release. Nanoscale 5(3), 1143–1152 (2013). Google Scholar
  177. 177.
    X.T. Zheng, P. Chen, C.M. Li, Anticancer efficacy and subcellular site of action investigated by real-time monitoring of cellular responses to localized drug delivery in single cells. Small 8(17), 2670–2674 (2012). Google Scholar
  178. 178.
    M. Kakran, N.G. Sahoo, H. Bao, Y. Pan, L. Li, Functionalized graphene oxide as nanocarrier for loading and delivery of ellagic acid. Curr. Med. Chem. 18(29), 4503–4512 (2011). Google Scholar
  179. 179.
    S. Gurunathan, J.W. Han, A.A. Dayem, V. Eppakayala, M.-R. Park, D.-N. Kwon, J.-H. Kim, Antibacterial activity of dithiothreitol reduced graphene oxide. J. Ind. Eng. Chem. 19(4), 1280–1288 (2013). Google Scholar
  180. 180.
    S. Liu, T.H. Zeng, M. Hofmann, E. Burcombe, J. Wei, R. Jiang, J. Kong, Y. Chen, Antibacterial activity of graphite, graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress. ACS Nano 5(9), 6971–6980 (2011). Google Scholar
  181. 181.
    B.Z. Ristic, M.M. Milenkovic, I.R. Dakic, B.M. Todorovic-Markovic, M.S. Milosavljevic et al., Photodynamic antibacterial effect of graphene quantum dots. Biomaterials 35(15), 4428–4435 (2014). Google Scholar
  182. 182.
    D. Zhang, X. Liu, X. Wang, Green synthesis of graphene oxide sheets decorated by silver nanoprisms and their anti-bacterial properties. J. Inorg. Biochem. 105(9), 1181–1186 (2011). Google Scholar
  183. 183.
    A.F. de Faria, D.S.T. Martinez, S.M.M. Meira, A.C.M. de Moraes, A. Brandelli, A.G.S. Filho, O.L. Alves, Anti-adhesion and antibacterial activity of silver nanoparticles supported on graphene oxide sheets. Colloid Surfaces B 113, 115–124 (2014). Google Scholar
  184. 184.
    S. Vijay Kumar, N.M. Huang, H.N. Lim, A.R. Marlinda, I. Harrison, C.H. Chia, One-step size-controlled synthesis of functional graphene oxide/silver nanocomposites at room temperature. Chem. Eng. J. 219, 217–224 (2013). Google Scholar
  185. 185.
    Z. Zhu, M. Su, L. Ma, L. Ma, D. Liu, Z. Wang, Preparation of graphene oxide–silver nanoparticle nanohybrids with highly antibacterial capability. Talanta 117, 449–455 (2013). Google Scholar
  186. 186.
    M.R. Das, R.K. Sarma, R. Saikia, V.S. Kale, M.V. Shelke, P. Sengupta, Synthesis of silver nanoparticles in an aqueous suspension of graphene oxide sheets and its antimicrobial activity. Colloid Surfaces B 83(1), 16–22 (2011). Google Scholar
  187. 187.
    M.R. Das, R.K. Sarma, S.C. Borah, R. Kumari, R. Saikia et al., The synthesis of citrate-modified silver nanoparticles in an aqueous suspension of graphene oxide nanosheets and their antibacterial activity. Colloid Surfaces B 105, 128–136 (2013). Google Scholar
  188. 188.
    M.S. Haider, A.C. Badejo, G.N. Shao, S.M. Imran, N. Abbas, Y.G. Chai, M. Hussain, H.T. Kim, Sequential repetitive chemical reduction technique to study size-property relationships of graphene attached ag nanoparticle. Solid State Sci. 44, 1–9 (2015). Google Scholar
  189. 189.
    V.H. Nguyen, B.-K. Kim, Y.-L. Jo, J.-J. Shim, Preparation and antibacterial activity of silver nanoparticles-decorated graphene composites. J. Supercrit. Fluid. 72, 28–35 (2012). Google Scholar
  190. 190.
    Q. Bao, D. Zhang, P. Qi, Synthesis and characterization of silver nanoparticle and graphene oxide nanosheet composites as a bactericidal agent for water disinfection. J. Colloid Interface Sci. 360(2), 463–470 (2011). Google Scholar
  191. 191.
    J. Shen, T. Li, M. Shi, N. Li, M. Ye, Polyelectrolyte-assisted one-step hydrothermal synthesis of ag-reduced graphene oxide composite and its antibacterial properties. Mater. Sci. Eng., C 32(7), 2042–2047 (2012). Google Scholar
  192. 192.
    X. Cai, M. Lin, S. Tan, W. Mai, Y. Zhang, Z. Liang, Z. Lin, X. Zhang, The use of polyethyleneimine-modified reduced graphene oxide as a substrate for silver nanoparticles to produce a material with lower cytotoxicity and long-term antibacterial activity. Carbon 50(10), 3407–3415 (2012). Google Scholar
  193. 193.
    H. Zhou, Y. Liu, W. Chi, C. Yu, Y. Yu, Preparation and antibacterial properties of ag@polydopamine/graphene oxide sheet nanocomposite. Appl. Surf. Sci. 282, 181–185 (2013). Google Scholar
  194. 194.
    Z. Tai, H. Ma, B. Liu, X. Yan, Q. Xue, Facile synthesis of Ag/GNS-g-PAA nanohybrids for antimicrobial applications. Colloid Surfaces B 89, 147–151 (2012). Google Scholar
  195. 195.
    B. Pant, P. Pokharel, A.P. Tiwari, P.S. Saud, M. Park, Z.K. Ghouri, S. Choi, S.-J. Park, H.-Y. Kim, Characterization and antibacterial properties of aminophenol grafted and ag nps decorated graphene nanocomposites. Ceram. Int. 41(4), 5656–5662 (2015). Google Scholar
  196. 196.
    M.K. Joshi, H.R. Pant, H.J. Kim, J.H. Kim, C.S. Kim, One-pot synthesis of ag-iron oxide/reduced graphene oxide nanocomposite via hydrothermal treatment. Colloid Surf. A-Physicochem. Eng. Asp. 446, 102–108 (2014). Google Scholar
  197. 197.
    L. Liu, H. Bai, J. Liu, D.D. Sun, Multifunctional graphene oxide-tio2-ag nanocomposites for high performance water disinfection and decontamination under solar irradiation. J. Hazard. Mater. 261, 214–223 (2013). Google Scholar
  198. 198.
    C.-H. Deng, J.-L. Gong, G.-M. Zeng, C.-G. Niu, Q.-Y. Niu, W. Zhang, H.-Y. Liu, Inactivation performance and mechanism of escherichia coli in aqueous system exposed to iron oxide loaded graphene nanocomposites. J. Hazard. Mater. 276, 66–76 (2014). Google Scholar
  199. 199.
    S. Bykkam, S. Narsingam, M. Ahmadipour, T. Dayakar, K. Venkateswara Rao, C. Shilpa Chakra, S. Kalakotla, Few layered graphene sheet decorated by zno nanoparticles for anti-bacterial application. Superlattices Microstruct. 83, 776–784 (2015). Google Scholar
  200. 200.
    T. Kavitha, A.I. Gopalan, K.-P. Lee, S.-Y. Park, Glucose sensing, photocatalytic and antibacterial properties of graphene–ZnO nanoparticle hybrids. Carbon 50(8), 2994–3000 (2012). Google Scholar
  201. 201.
    S. Cao, C. Chen, J. Zhang, C. Zhang, W. Yu, B. Liang, Y. Tsang, Mnox quantum dots decorated reduced graphene oxide/TiO2 nanohybrids for enhanced activity by a UV pre-catalytic microwave method. Appl. Catal. B-Environ. 176–177, 500–512 (2015). Google Scholar
  202. 202.
    S. Chella, P. Kollu, E.V.P.R. Komarala, S. Doshi, M. Saranya et al., Solvothermal synthesis of MnFe2O4–graphene composite—investigation of its adsorption and antimicrobial properties. Appl. Surf. Sci. 327, 27–36 (2015). Google Scholar
  203. 203.
    Y.-N. Chang, X.-M. Ou, G.-M. Zeng, J.-L. Gong, C.-H. Deng et al., Synthesis of magnetic graphene oxide–TiO2 and their antibacterial properties under solar irradiation. Appl. Surf. Sci. 343, 1–10 (2015). Google Scholar
  204. 204.
    C. Chen, S. Cao, W. Yu, X. Xie, Q. Liu, Y. Tsang, Y. Xiao, Adsorption, photocatalytic and sunlight-driven antibacterial activity of bi2wo6/graphene oxide nanoflakes. Vacuum 116, 48–53 (2015). Google Scholar
  205. 205.
    T. Li, J. Shen, N. Li, M. Ye, Facile in situ synthesis of hydrophilic rgo–cd–ag supramolecular hybrid and its enhanced antibacterial properties. Mater. Sci. Eng., C 39, 352–358 (2014). Google Scholar
  206. 206.
    C.-H. Deng, J.-L. Gong, G.-M. Zeng, Y. Jiang, C. Zhang, H.-Y. Liu, S.-Y. Huan, Graphene–cds nanocomposite inactivation performance toward escherichia coli in the presence of humic acid under visible light irradiation. Chem. Eng. J. 284, 41–53 (2016). Google Scholar
  207. 207.
    P. Li, S. Sun, A. Dong, Y. Hao, S. Shi, Z. Sun, G. Gao, Y. Chen, Developing of a novel antibacterial agent by functionalization of graphene oxide with guanidine polymer with enhanced antibacterial activity. Appl. Surf. Sci. 355, 446–452 (2015). Google Scholar
  208. 208.
    H.N. Lim, N.M. Huang, C.H. Loo, Facile preparation of graphene-based chitosan films: enhanced thermal, mechanical and antibacterial properties. J. Non Cryst. Solids 358(3), 525–530 (2012). Google Scholar
  209. 209.
    M. Haniff Wahid, U.H. Stroeher, E. Eroglu, X. Chen, K. Vimalanathan, C.L. Raston, R.A. Boulos, Aqueous based synthesis of antimicrobial-decorated graphene. J. Colloid Interface Sci. 443, 88–96 (2015). Google Scholar
  210. 210.
    A. Soroush, W. Ma, M. Cyr, M.S. Rahaman, B. Asadishad, N. Tufenkji, In situ silver decoration on graphene oxide-treated thin film composite forward osmosis membranes: biocidal properties and regeneration potential. Environ. Sci. Technol. Lett. 3(1), 13–18 (2015). Google Scholar
  211. 211.
    V. Vatanpour, A. Shockravi, H. Zarrabi, Z. Nikjavan, A. Javadi, Fabrication and characterization of anti-fouling and anti-bacterial ag-loaded graphene oxide/polyethersulfone mixed matrix membrane. J. Ind. Eng. Chem. 30, 342–352 (2015). Google Scholar
  212. 212.
    X.-F. Sun, J. Qin, P.-F. Xia, B.-B. Guo, C.-M. Yang, C. Song, S.-G. Wang, Graphene oxide–silver nanoparticle membrane for biofouling control and water purification. Chem. Eng. J. 281, 53–59 (2015). Google Scholar
  213. 213.
    M. Mazaheri, O. Akhavan, A. Simchi, Flexible bactericidal graphene oxide–chitosan layers for stem cell proliferation. Appl. Surf. Sci. 301, 456–462 (2014). Google Scholar
  214. 214.
    Y. Liu, M. Park, H.K. Shin, B. Pant, J. Choi, Y.W. Park, J.Y. Lee, S.-J. Park, H.-Y. Kim, Facile preparation and characterization of poly(vinyl alcohol)/chitosan/graphene oxide biocomposite nanofibers. J. Ind. Eng. Chem. 20(6), 4415–4420 (2014). Google Scholar
  215. 215.
    L. Duan, Y. Wang, Y. Zhang, J. Liu, Graphene immobilized enzyme/polyethersulfone mixed matrix membrane: enhanced antibacterial, permeable and mechanical properties. Appl. Surf. Sci. 355, 436–445 (2015). Google Scholar
  216. 216.
    F. Perreault, M.E. Tousley, M. Elimelech, Thin-film composite polyamide membranes functionalized with biocidal graphene oxide nanosheets. Environ. Sci. Technol. Lett. 1(1), 71–76 (2013). Google Scholar
  217. 217.
    L. He, L.F. Dumée, C. Feng, L. Velleman, R. Reis, F. She, W. Gao, L. Kong, Promoted water transport across graphene oxide–poly(amide) thin film composite membranes and their antibacterial activity. Desalination 365, 126–135 (2015). Google Scholar
  218. 218.
    Z.-B. Zhang, J.-J. Wu, Y. Su, J. Zhou, Y. Gao, H.-Y. Yu, J.-S. Gu, Layer-by-layer assembly of graphene oxide on polypropylene macroporous membranes via click chemistry to improve antibacterial and antifouling performance. Appl. Surf. Sci. 332, 300–307 (2015). Google Scholar
  219. 219.
    R. Major, M. Sanak, A. Mzyk, L. Lipinska, M. Kot, P. Lacki, F. Bruckert, B. Major, Graphene based porous coatings with antibacterial and antithrombogenous function—materials and design. Arch. Civ. Mech. Eng. 14(4), 540–549 (2014). Google Scholar
  220. 220.
    C. Bora, P. Bharali, S. Baglari, S.K. Dolui, B.K. Konwar, Strong and conductive reduced graphene oxide/polyester resin composite films with improved mechanical strength, thermal stability and its antibacterial activity. Compos. Sci. Technol 87, 1–7 (2013). Google Scholar
  221. 221.
    H.M. Hegab, A. ElMekawy, T.G. Barclay, A. Michelmore, L. Zou, C.P. Saint, M. Ginic-Markovic, Fine-tuning the surface of forward osmosis membranes via grafting graphene oxide: performance patterns and biofouling propensity. ACS Appl. Mater. Interfaces. 7(32), 18004–18016 (2015). Google Scholar
  222. 222.
    L. Yu, Y. Zhang, B. Zhang, J. Liu, H. Zhang, C. Song, Preparation and characterization of hpei-go/pes ultrafiltration membrane with antifouling and antibacterial properties. J. Membr. Sci. 447, 452–462 (2013). Google Scholar
  223. 223.
    A. Nourmohammadi, R. Rahighi, O. Akhavan, A. Moshfegh, Graphene oxide sheets involved in vertically aligned zinc oxide nanowires for visible light photoinactivation of bacteria. J. Alloys Compd. 612, 380–385 (2014). Google Scholar
  224. 224.
    O. Akhavan, E. Ghaderi, Toxicity of graphene and graphene oxide nanowalls against bacteria. ACS Nano 4(10), 5731–5736 (2010). Google Scholar
  225. 225.
    A. Janković, S. Eraković, M. Vukašinović-Sekulić, V. Mišković-Stanković, S.J. Park, K.Y. Rhee, Graphene-based antibacterial composite coatings electrodeposited on titanium for biomedical applications. Prog. Org. Coat. 83, 1–10 (2015). Google Scholar
  226. 226.
    L. Dellieu, E. Lawarée, N. Reckinger, C. Didembourg, J.J. Letesson, M. Sarrazin, O. Deparis, J.Y. Matroule, J.F. Colomer, Do CVD grown graphene films have antibacterial activity on metallic substrates? Carbon 84, 310–316 (2015). Google Scholar
  227. 227.
    X. Wang, Z. Liu, X. Ye, K. Hu, H. Zhong, X. Yuan, H. Xiong, Z. Guo, A facile one-pot method to two kinds of graphene oxide-based hydrogels with broad-spectrum antimicrobial properties. Chem. Eng. J. 260, 331–337 (2015). Google Scholar
  228. 228.
    Y. Wang, P. Zhang, C.F. Liu, C.Z. Huang, A facile and green method to fabricate graphene-based multifunctional hydrogels for miniature-scale water purification. RSC Adv. 3(24), 9240–9246 (2013). Google Scholar
  229. 229.
    R. Surudžić, A. Janković, N. Bibić, M. Vukašinović-Sekulić, A. Perić-Grujić, V. Mišković-Stanković, S.J. Park, K.Y. Rhee, Physico–chemical and mechanical properties and antibacterial activity of silver/poly(vinyl alcohol)/graphene nanocomposites obtained by electrochemical method. Compos. Part B-Eng. 85, 102–112 (2016). Google Scholar
  230. 230.
    Q. Liu, B. Guo, Z. Rao, B. Zhang, J.R. Gong, Strong two-photon-induced fluorescence from photostable, biocompatible nitrogen-doped graphene quantum dots for cellular and deep-tissue imaging. Nano Lett. 13(6), 2436–2441 (2013). Google Scholar
  231. 231.
    Z. Sun, P. Huang, G. Tong, J. Lin, A. Jin et al., Vegf-loaded graphene oxide as theranostics for multi-modality imaging-monitored targeting therapeutic angiogenesis of ischemic muscle. Nanoscale 5(15), 6857–6866 (2013). Google Scholar
  232. 232.
    K. Yang, S. Zhang, G. Zhang, X. Sun, S.-T. Lee, Z. Liu, Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 10(9), 3318–3323 (2010). Google Scholar
  233. 233.
    Z. Liu, Z. Guo, H. Zhong, X. Qin, M. Wan, B. Yang, Graphene oxide based surface-enhanced raman scattering probes for cancer cell imaging. Phys. Chem. Chem. Phys. 15(8), 2961–2966 (2013). Google Scholar
  234. 234.
    X. Ma, Q. Qu, Y. Zhao, Z. Luo, Y. Zhao, K.W. Ng, Y. Zhao, Graphene oxide wrapped gold nanoparticles for intracellular raman imaging and drug delivery. J. Mater. Chem. B 1(47), 6495–6500 (2013). Google Scholar
  235. 235.
    Y. Wang, L. Polavarapu, L.M. Liz-Marzán, Reduced graphene oxide-supported gold nanostars for improved sers sensing and drug delivery. ACS Appl. Mater. Interfaces. 6(24), 21798–21805 (2014). Google Scholar
  236. 236.
    J. Huang, L. Zhang, B. Chen, N. Ji, F. Chen, Y. Zhang, Z. Zhang, Nanocomposites of size-controlled gold nanoparticles and graphene oxide: formation and applications in sers and catalysis. Nanoscale 2(12), 2733–2738 (2010). Google Scholar
  237. 237.
    J. Huang, C. Zong, H. Shen, M. Liu, B. Chen, B. Ren, Z. Zhang, Mechanism of cellular uptake of graphene oxide studied by surface-enhanced Raman spectroscopy. Small 8(16), 2577–2584 (2012). Google Scholar
  238. 238.
    Z.-L. Song, Z. Chen, X. Bian, L.-Y. Zhou, D. Ding et al., Alkyne-functionalized superstable graphitic silver nanoparticles for raman imaging. J. Am. Chem. Soc. 136(39), 13558–13561 (2014). Google Scholar
  239. 239.
    H. Hong, K. Yang, Y. Zhang, J.W. Engle, L. Feng et al., In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 6(3), 2361–2370 (2012). Google Scholar
  240. 240.
    H. Hong, Y. Zhang, J.W. Engle, T.R. Nayak, C.P. Theuer, R.J. Nickles, T.E. Barnhart, W. Cai, In vivo targeting and positron emission tomography imaging of tumor vasculature with 66ga-labeled nano-graphene. Biomaterials 33(16), 4147–4156 (2012). Google Scholar
  241. 241.
    Y. Fazaeli, O. Akhavan, R. Rahighi, M.R. Aboudzadeh, E. Karimi, H. Afarideh, In vivo spect imaging of tumors by 198,199au-labeled graphene oxide nanostructures. Mater. Sci. Eng., C 45, 196–204 (2014). Google Scholar
  242. 242.
    H.-W. Yang, C.-Y. Huang, C.-W. Lin, H.-L. Liu, C.-W. Huang et al., Gadolinium-functionalized nanographene oxide for combined drug and microrna delivery and magnetic resonance imaging. Biomaterials 35(24), 6534–6542 (2014). Google Scholar
  243. 243.
    K. Yang, L. Hu, X. Ma, S. Ye, L. Cheng, X. Shi, C. Li, Y. Li, Z. Liu, Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv. Mater. 24(14), 1867 (2012). Google Scholar
  244. 244.
    Y.H. Hu, The first magnetic-nanoparticle-free carbon-based contrast agent of magnetic-resonance imaging-fluorinated graphene oxide. Small 10(8), 1451–1452 (2013). Google Scholar
  245. 245.
    G. Lalwani, X. Cai, L. Nie, L.V. Wang, B. Sitharaman, Graphene-based contrast agents for photoacoustic and thermoacoustic tomography. Photoacoustics 1(3–4), 62–67 (2013). Google Scholar
  246. 246.
    Y.-W. Wang, Y.-Y. Fu, Q. Peng, S.-S. Guo, G. Liu, J. Li, H.-H. Yang, G.-N. Chen, Dye-enhanced graphene oxide for photothermal therapy and photoacoustic imaging. J. Mater. Chem. B 1(42), 5762–5767 (2013). Google Scholar
  247. 247.
    Z. Sheng, L. Song, J. Zheng, D. Hu, M. He et al., Protein-assisted fabrication of nano-reduced graphene oxide for combined in vivo photoacoustic imaging and photothermal therapy. Biomaterials 34(21), 5236–5243 (2013). Google Scholar
  248. 248.
    J. Shi, L. Wang, J. Zhang, R. Ma, J. Gao, Y. Liu, C. Zhang, Z. Zhang, A tumor-targeting near-infrared laser-triggered drug delivery system based on go@ag nanoparticles for chemo-photothermal therapy and x-ray imaging. Biomaterials 35(22), 5847–5861 (2014). Google Scholar
  249. 249.
    H. Zhang, H. Wu, J. Wang, Y. Yang, D. Wu, Y. Zhang, Y. Zhang, Z. Zhou, S. Yang, Graphene oxide-BaGdF5 nanocomposites for multi-modal imaging and photothermal therapy. Biomaterials 42, 66–77 (2015). Google Scholar
  250. 250.
    X. Shi, H. Gong, Y. Li, C. Wang, L. Cheng, Z. Liu, Graphene-based magnetic plasmonic nanocomposite for dual bioimaging and photothermal therapy. Biomaterials 34(20), 4786–4793 (2013). Google Scholar
  251. 251.
    H. Zhou, K. Zhao, W. Li, N. Yang, Y. Liu, C. Chen, T. Wei, The interactions between pristine graphene and macrophages and the production of cytokines/chemokines via tlr- and nf-κb-related signaling pathways. Biomaterials 33(29), 6933–6942 (2012). Google Scholar
  252. 252.
    Y. Li, Y. Liu, Y. Fu, T. Wei, L. Le Guyader, G. Gao, R.-S. Liu, Y.-Z. Chang, C. Chen, The triggering of apoptosis in macrophages by pristine graphene through the MAPK and TGF-beta signaling pathways. Biomaterials 33(2), 402–411 (2012). Google Scholar
  253. 253.
    A. Sasidharan, L.S. Panchakarla, A.R. Sadanandan, A. Ashokan, P. Chandran et al., Hemocompatibility and macrophage response of pristine and functionalized graphene. Small 8(8), 1251–1263 (2012). Google Scholar
  254. 254.
    Y. Li, H. Yuan, A. von dem Bussche, M. Creighton, R.H. Hurt, A.B. Kane, H. Gao, Graphene microsheets enter cells through spontaneous membrane penetration at edge asperities and corner sites. Proc. Natl. Acad. Sci. U.S.A. 110(30), 12295–12300 (2013). Google Scholar
  255. 255.
    H. Mao, W. Chen, S. Laurent, C. Thirifays, C. Burtea, F. Rezaee, M. Mahmoudi, Hard corona composition and cellular toxicities of the graphene sheets. Colloid Surfaces B 109, 212–218 (2013). Google Scholar
  256. 256.
    Y. Qin, Z.-W. Zhou, S.-T. Pan, Z.-X. He, X. Zhang, J.-X. Qiu, W. Duan, T. Yang, S.-F. Zhou, Graphene quantum dots induce apoptosis, autophagy, and inflammatory response via p38 mitogen-activated protein kinase and nuclear factor-κb mediated signaling pathways in activated thp-1 macrophages. Toxicology 327, 62–76 (2015). Google Scholar
  257. 257.
    M.C. Duch, G.R.S. Budinger, Y.T. Liang, S. Soberanes, D. Urich et al., Minimizing oxidation and stable nanoscale dispersion improves the biocompatibility of graphene in the lung. Nano Lett. 11(12), 5201–5207 (2011). Google Scholar
  258. 258.
    H. Zhou, B. Zhang, J. Zheng, M. Yu, T. Zhou et al., The inhibition of migration and invasion of cancer cells by graphene via the impairment of mitochondrial respiration. Biomaterials 35(5), 1597–1607 (2014). Google Scholar
  259. 259.
    T. Lammel, P. Boisseaux, M.-L. Fernández-Cruz, J.M. Navas, Internalization and cytotoxicity of graphene oxide and carboxyl graphene nanoplatelets in the human hepatocellular carcinoma cell line hep g2. Part. Fibre Toxicol. 10(1), 27 (2013). Google Scholar
  260. 260.
    N. Chatterjee, H.-J. Eom, J. Choi, A systems toxicology approach to the surface functionality control of graphene–cell interactions. Biomaterials 35(4), 1109–1127 (2014). Google Scholar
  261. 261.
    Y. Li, Q. Wu, Y. Zhao, Y. Bai, P. Chen, T. Xia, D. Wang, Response of micrornas to in vitro treatment with graphene oxide. ACS Nano 8(3), 2100–2110 (2014). Google Scholar
  262. 262.
    M.-C. Matesanz, M. Vila, M.-J. Feito, J. Linares, G. Gonçalves, M. Vallet-Regi, P.-A.A.P. Marques, M.-T. Portolés, The effects of graphene oxide nanosheets localized on f-actin filaments on cell-cycle alterations. Biomaterials 34(5), 1562–1569 (2013). Google Scholar
  263. 263.
    Y. Li, Z. Lu, Z. Li, G. Nie, Y. Fang, Cellular uptake and distribution of graphene oxide coated with layer-by-layer assembled polyelectrolytes. J. Nanopart. Res. 16(5), 2384 (2014). Google Scholar
  264. 264.
    K.-H. Liao, Y.-S. Lin, C.W. Macosko, C.L. Haynes, Cytotoxicity of graphene oxide and graphene in human erythrocytes and skin fibroblasts. ACS Appl. Mater. Interfaces. 3(7), 2607–2615 (2011). Google Scholar
  265. 265.
    W. Zhang, L. Yan, M. Li, R. Zhao, X. Yang et al., Deciphering the underlying mechanisms of oxidation-state dependent cytotoxicity of graphene oxide on mammalian cells. Toxicol. Lett. 237(2), 61–71 (2015). Google Scholar
  266. 266.
    K. Wang, J. Ruan, H. Song, J. Zhang, Y. Wo, S. Guo, D. Cui, Biocompatibility of graphene oxide. Nanoscale Res. Lett. 6, 8 (2010). Google Scholar
  267. 267.
    M. Papi, M.C. Lauriola, V. Palmieri, G. Ciasca, G. Maulucci, M. De Spirito, Plasma protein corona reduces the haemolytic activity of graphene oxide nano and micro flakes. RSC Adv. 5(99), 81638–81641 (2015). Google Scholar
  268. 268.
    W. Hu, C. Peng, M. Lv, X. Li, Y. Zhang, N. Chen, C. Fan, Q. Huang, Protein corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano 5(5), 3693–3700 (2011). Google Scholar
  269. 269.
    H. Yue, W. Wei, Z. Yue, B. Wang, N. Luo, Y. Gao, D. Ma, G. Ma, Z. Su, The role of the lateral dimension of graphene oxide in the regulation of cellular responses. Biomaterials 33(16), 4013–4021 (2012). Google Scholar
  270. 270.
    G. Qu, S. Liu, S. Zhang, L. Wang, X. Wang et al., Graphene oxide induces toll-like receptor 4 (tlr4)-dependent necrosis in macrophages. ACS Nano 7(7), 5732–5745 (2013). Google Scholar
  271. 271.
    J. Russier, E. Treossi, A. Scarsi, F. Perrozzi, H. Dumortier, L. Ottaviano, M. Meneghetti, V. Palermo, A. Bianco, Evidencing the mask effect of graphene oxide: a comparative study on primary human and murine phagocytic cells. Nanoscale 5(22), 11234–11247 (2013). Google Scholar
  272. 272.
    X. Zhi, H. Fang, C. Bao, G. Shen, J. Zhang, K. Wang, S. Guo, T. Wan, D. Cui, The immunotoxicity of graphene oxides and the effect of pvp-coating. Biomaterials 34(21), 5254–5261 (2013). Google Scholar
  273. 273.
    C. Jin, F. Wang, Y. Tang, X. Zhang, J. Wang, Y. Yang, Distribution of graphene oxide and TiO2–graphene oxide composite in a549 cells. Biol. Trace Elem. Res. 159(1–3), 393–398 (2014). Google Scholar
  274. 274.
    Z. Yang, C. Ge, J. Liu, Y. Chong, Z. Gu, C.A. Jimenez-Cruz, Z. Chai, R. Zhou, Destruction of amyloid fibrils by graphene through penetration and extraction of peptides. Nanoscale 7(44), 18725–18737 (2015). Google Scholar
  275. 275.
    J. Park, B. Kim, J. Han, J. Oh, S. Park et al., Graphene oxide flakes as a cellular adhesive: prevention of reactive oxygen species mediated death of implanted cells for cardiac repair. ACS Nano 9(5), 4987–4999 (2015). Google Scholar
  276. 276.
    J. Linares, M.C. Matesanz, M. Vila, M.J. Feito, G. Gonçalves, M. Vallet-Regí, P.A.A.P. Marques, M.T. Portolés, Endocytic mechanisms of graphene oxide nanosheets in osteoblasts, hepatocytes and macrophages. ACS Appl. Mater. Interfaces. 6(16), 13697–13706 (2014). Google Scholar
  277. 277.
    Q. Mu, G. Su, L. Li, B.O. Gilbertson, L.H. Yu, Q. Zhang, Y.-P. Sun, B. Yan, Size-dependent cell uptake of protein-coated graphene oxide nanosheets. ACS Appl. Mater. Interfaces. 4(4), 2259–2266 (2012). Google Scholar
  278. 278.
    T. Zhou, B. Zhang, P. Wei, Y. Du, H. Zhou et al., Energy metabolism analysis reveals the mechanism of inhibition of breast cancer cell metastasis by PEG-modified graphene oxide nanosheets. Biomaterials 35(37), 9833–9843 (2014). Google Scholar
  279. 279.
    Z. Liu, J.T. Robinson, X. Sun, H. Dai, Pegylated nanographene oxide for delivery of water-insoluble cancer drugs. J. Am. Chem. Soc. 130(33), 10876–10877 (2008). Google Scholar
  280. 280.
    Y. Zeng, Z. Yang, S. Luo, H. Li, C. Liu, Y. Hao, J. Liu, W. Wang, R. Li, Fast and facile preparation of pegylated graphene from graphene oxide by lysosome targeting delivery of photosensitizer to efficiently enhance photodynamic therapy. RSC Adv. 5(71), 57725–57734 (2015). Google Scholar
  281. 281.
    S. Mullick Chowdhury, G. Lalwani, K. Zhang, J.Y. Yang, K. Neville, B. Sitharaman, Cell specific cytotoxicity and uptake of graphene nanoribbons. Biomaterials 34(1), 283–293 (2013). Google Scholar
  282. 282.
    S. Mullick Chowdhury, P. Manepalli, B. Sitharaman, Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein. Acta Biomater. 10(10), 4494–4504 (2014). Google Scholar
  283. 283.
    D.A. Mbeh, O. Akhavan, T. Javanbakht, M. Mahmoudi, L.H. Yahia, Cytotoxicity of protein corona-graphene oxide nanoribbons on human epithelial cells. Appl. Surf. Sci. 320, 596–601 (2014). Google Scholar
  284. 284.
    Y. Talukdar, J.T. Rashkow, G. Lalwani, S. Kanakia, B. Sitharaman, The effects of graphene nanostructures on mesenchymal stem cells. Biomaterials 35(18), 4863–4877 (2014). Google Scholar
  285. 285.
    Y. Chong, C. Ge, Z. Yang, J.A. Garate, Z. Gu, J.K. Weber, J. Liu, R. Zhou, Reduced cytotoxicity of graphene nanosheets mediated by blood-protein coating. ACS Nano 9(6), 5713–5724 (2015). Google Scholar
  286. 286.
    S. Das, S. Singh, V. Singh, D. Joung, J.M. Dowding et al., Oxygenated functional group density on graphene oxide: its effect on cell toxicity. Part. Part. Syst. Charact. 30(2), 148–157 (2013). Google Scholar
  287. 287.
    L. Horváth, A. Magrez, M. Burghard, K. Kern, L. Forró, B. Schwaller, Evaluation of the toxicity of graphene derivatives on cells of the lung luminal surface. Carbon 64, 45–60 (2013). Google Scholar
  288. 288.
    W. Miao, G. Shim, G. Kim, S. Lee, H.-J. Lee, Y.B. Kim, Y. Byun, Y.-K. Oh, Image-guided synergistic photothermal therapy using photoresponsive imaging agent-loaded graphene-based nanosheets. J. Control. Release 211, 28–36 (2015). Google Scholar
  289. 289.
    M.-G. Kim, J.Y. Park, W. Miao, J. Lee, Y.-K. Oh, Polyaptamer DNA nanothread-anchored, reduced graphene oxide nanosheets for targeted delivery. Biomaterials 48, 129–136 (2015). Google Scholar
  290. 290.
    C. Cheng, S. Nie, S. Li, H. Peng, H. Yang, L. Ma, S. Sun, C. Zhao, Biopolymer functionalized reduced graphene oxide with enhanced biocompatibility via mussel inspired coatings/anchors. J. Mater. Chem. B 1(3), 265–275 (2013). Google Scholar
  291. 291.
    O. Akhavan, E. Ghaderi, A. Akhavan, Size-dependent genotoxicity of graphene nanoplatelets in human stem cells. Biomaterials 33(32), 8017–8025 (2012). Google Scholar
  292. 292.
    S.K. Singh, M.K. Singh, M.K. Nayak, S. Kumari, S. Shrivastava, J.J.A. Grácio, D. Dash, Thrombus inducing property of atomically thin graphene oxide sheets. ACS Nano 5(6), 4987–4996 (2011). Google Scholar
  293. 293.
    S.K. Singh, M.K. Singh, P.P. Kulkarni, V.K. Sonkar, J.J.A. Grácio, D. Dash, Amine-modified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications. ACS Nano 6(3), 2731–2740 (2012). Google Scholar
  294. 294.
    A. Chwalibog, S. Jaworski, E. Sawosz, M. Kutwin, M. Wierzbicki et al., In vitro and in vivo effects of graphene oxide and reduced graphene oxide on glioblastoma. Int. J. Nanomed. 10(1), 1585–1596 (2015). Google Scholar
  295. 295.
    E. Sawosz, S. Jaworski, M. Kutwin, K. Vadalasetty, M. Grodzik et al., Graphene functionalized with arginine decreases the development of glioblastoma multiforme tumor in a gene-dependent manner. Int. J. Mol. Sci. 16(10), 25214–25233 (2015). Google Scholar
  296. 296.
    J.H. Shin, S.G. Han, J.K. Kim, B.W. Kim, J.H. Hwang et al., 5-day repeated inhalation and 28-day post-exposure study of graphene. Nanotoxicology 9(8), 1023–1031 (2015). Google Scholar
  297. 297.
    Y.H. Kim, M.S. Jo, J.K. Kim, J.H. Shin, J.E. Baek et al., Short-term inhalation study of graphene oxide nanoplates. Nanotoxicology 12(3), 224–238 (2018). Google Scholar
  298. 298.
    J.K. Kim, J.H. Shin, J.S. Lee, J.H. Hwang, J.H. Lee et al., 28-day inhalation toxicity of graphene nanoplatelets in Sprague–Dawley rats. Nanotoxicology 10(7), 891–901 (2016). Google Scholar
  299. 299.
    B. Li, J. Yang, Q. Huang, Y. Zhang, C. Peng et al., Biodistribution and pulmonary toxicity of intratracheally instilled graphene oxide in mice. NPG Asia Mater. 5(4), e44 (2013). Google Scholar
  300. 300.
    L. Mao, M. Hu, B. Pan, Y. Xie, E.J. Petersen, Biodistribution and toxicity of radio-labeled few layer graphene in mice after intratracheal instillation. Part. Fibre Toxicol. 13(1), 7 (2015). Google Scholar
  301. 301.
    A. Schinwald, F. Murphy, A. Askounis, V. Koutsos, K. Sefiane, K. Donaldson, C.J. Campbell, Minimal oxidation and inflammogenicity of pristine graphene with residence in the lung. Nanotoxicology 8(8), 824–832 (2013). Google Scholar
  302. 302.
    A. Schinwald, F.A. Murphy, A. Jones, W. MacNee, K. Donaldson, Graphene-based nanoplatelets: a new risk to the respiratory system as a consequence of their unusual aerodynamic properties. ACS Nano 6(1), 736–746 (2012). Google Scholar
  303. 303.
    S.G. Han, J.K. Kim, J.H. Shin, J.H. Hwang, J.S. Lee et al., Pulmonary responses of Sprague–Dawley rats in single inhalation exposure to graphene oxide nanomaterials. Biomed. Res. Int. 2015, 1–9 (2015). Google Scholar
  304. 304.
    S. Liang, S. Xu, D. Zhang, J. He, M. Chu, Reproductive toxicity of nanoscale graphene oxide in male mice. Nanotoxicology 9(1), 92–105 (2014). Google Scholar
  305. 305.
    X. Zhang, J. Yin, C. Peng, W. Hu, Z. Zhu, W. Li, C. Fan, Q. Huang, Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. Carbon 49(3), 986–995 (2011). Google Scholar
  306. 306.
    B. Li, X. Zhang, J. Yang, Y. Zhang, W. Li, C. Fan, Q. Huang, Influence of polyethylene glycol coating on biodistribution and toxicity of nanoscale graphene oxide in mice after intravenous injection. Int. J. Nanomed. 9(1), 4697–4707 (2014). Google Scholar
  307. 307.
    Y. Chong, Y. Ma, H. Shen, X. Tu, X. Zhou, J. Xu, J. Dai, S. Fan, Z. Zhang, The in vitro and in vivo toxicity of graphene quantum dots. Biomaterials 35(19), 5041–5048 (2014). Google Scholar
  308. 308.
    S.A. Sydlik, S. Jhunjhunwala, M.J. Webber, D.G. Anderson, R. Langer, In vivo compatibility of graphene oxide with differing oxidation states. ACS Nano 9(4), 3866–3874 (2015). Google Scholar
  309. 309.
    W.-Y. Pan, C.-C. Huang, T.-T. Lin, H.-Y. Hu, W.-C. Lin, M.-J. Li, H.-W. Sung, Synergistic antibacterial effects of localized heat and oxidative stress caused by hydroxyl radicals mediated by graphene/iron oxide-based nanocomposites. Nanomed. Nanotechnol. Biol. Med. 12(2), 431–438 (2016). Google Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Thabitha P. Dasari Shareena
    • 1
  • Danielle McShan
    • 1
  • Asok K. Dasmahapatra
    • 1
  • Paul B. Tchounwou
    • 1
    Email author
  1. 1.RCMI Center for Environmental HealthJackson State UniversityJacksonUSA

Personalised recommendations